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ABSTRACT 
Background 
Alternative exon usage (AEU) is an important component of gene expression regulation. Exon 
expression platforms allow the detection of associations between AEU and phenotypes such as 
cancer. Numerous studies have identified associations between gene expression and the brain 
cancer glioblastoma multiforme (GBM). The few consistent gene expression biomarkers of 
GBM that have been reported may be due to the limited consideration of AEU and the analytical 
approaches used. The objectives of this study were to develop a model that accounts for the 
variations in expression present between the exons within a gene and to identify AEU 
biomarkers of GBM survival. 
Methods 
The expression of exons corresponding to 25,403 genes was related to the survival of 250 
individuals diagnosed with GBM in a training data set. Genes exhibiting AEU in the training 
data set were confirmed in an independent validation data set of 78 patients. A hierarchical 
model allows the consideration of covariation between exons within a gene and of the effect of 
the epidemiological characteristics of the patients was developed to identify associations 
between exon expression and patient survival. The same model serves multi-exon models with 
and without AEU and single-exon models. 
Results 
AEU associated with GBM survival was identified on 2477 genes (P-value < 5.0E-04 (FDR 
adjusted P-value < 5.0E-04). G-protein coupled receptor 98 (Gpr98) and epidermal growth factor 
(Egf) were among the genes exhibiting AEU with 30 and 9 exons associated with GBM survival, 
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respectively. Pathways enriched among the AEU genes included focal adhesion, ECM-receptor 
interaction, ABC transporters and pathways in cancer. In addition, 24 multi-exon genes without 
AEU and 8 single-exon genes were associated with GBM survival (P-value < 0.0005).  
Conclusions 
The inferred patterns of AEU were consistent with in silico AS models. The hierarchical model 
used offered a flexible and simple way to interpret and identify associations between survival 
that accommodates multi-exon genes with or without AEU and single exon genes. 
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CHAPTER 1 
LITERATURE REVIEW 
Alternative Splicing of Genes 
Central Dogma and Alternative Splicing 
Gene regulation is an important aspect for life and is a fundamental process in all living cells. 
Various fundamental mechanisms such as transcriptional factor regulation, transcriptional 
machinery, reproduction, homeostasis and adaptation all contribute in regulating gene 
expression. Studies have revealed mechanisms such as chromatin modifications, transcription, 
splicing, other mRNA modifications, translation and post translational modifications impact gene 
expression [1]. In 1958 Crick proposed the “Central Dogma of Molecular Biology”, which 
enunciated the transfer of information between DNA, RNA and protein. According to central 
dogma the transfer of genetic information can be subdivided into three major categories: transfer 
with direct or indirect evidence (DNADNA, DNARNA and RNAProtein), transfer with 
no evidence (RNADNA and DNAProtein) and no transfer (ProteinProtein, 
ProteinDNA and ProteinRNA), where ‘’ represent the flow of information. Hence, 
according to central dogma genes are transcribed into RNA molecule and further translated into a 
polypeptide chain [2]. Another important concept “one gene one enzyme” was put forward by 
Beadle and Tatum in 1941, which in 1962 was modified to “one gene one polypeptide” by 
Ingram. The completion of Human Genome Project (HGP) lead scientists to establish that human 
genome consists of roughly 30,000 genes, where the genes present in the genome are of varying 
lengths. Gene can be defined as, “the complete sequence region necessary for generating a 
functional product”, including both protein-coding and non-coding RNA genes. Most of these 
genes consist of coding region that are expressed referred to as ‘exon’ and non-expressing 
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intervening sequences known as ‘intron’ (Figure 1.1) [3]. In 1977, Walter Gilbert became the 
first one to suggest the concept of exon and intron and suggested that different mRNA variant 
can be produced from the same gene by splicing various exonic combinations. Walter observed 
that genes of eukaryotes contained intervening sequences that were removed as post-
transcriptional modification and were referred to as ‘Introns. By 1980’s various studies 
recognized that Alternative Splicing (AS) as a natural process occurring in the genome by 
confirming the presence of different transcripts of the same gene. Based on the number of 
expressed sequence (mRNA), it was anticipated that humans would have a much larger genome 
than drosophila (14,000 genes), including approximately 150,000 genes. Estimates from different 
studies suggest that approximately 95% of all the human genes are subjected to AS [4]. 
However, the sequencing of human genome reported presence of some 32,000 genes which were 
far less than anticipated. This vast difference in human gene content led scientists to evaluate the 
importance AS in producing genomic variation [5]. Thus, an AS event is categorized by the 
formation of different isoforms, mRNAs with altered gene functions produced from the same 
locus possessing different protein coding DNA sequences (CDS), transcription start sites (TSS) 
and untranslated region (UTR), from the same transcript due to retaining different exonic 
segments and splicing different combinations of splice site together in the mRNA [6]. Thus, the 
phenomenon of AS is a vital cellular and regulatory process involved in regulating genes, as 
variety of processes ranging from cell growth and differentiation to apoptosis utilize AS for their 
proper functioning, and diversifying genome by compelling genes with multiple exons to 
produce distinct variants that in turn code for structurally and functionally distinct protein 
variants i.e. involved in regulating and generating genomic and proteomic diversity [7].  
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Alternative splicing can be divided into three broad categories; intron retention, cryptic splice 
site usage (functions by elongating or shortening the exon), and alternative exon usage (AEU). 
An AEU results in the skipping of exon and is also termed as alternative 5` to 3` splicing. 
Alternative exon usage is sub-divided into two categories: cassette exons (discrete exons that can 
be independently included or excluded) and mutually exclusive splicing (which involves the 
selection of only one from a group of two or more exon variants
 
[4]. 
 
Mechanism For Regulating Alternative Splicing 
A variety of genetic diseases manifest solely due to mutation in splice site sequences, 
spliceosome complex and auxiliary or cis-regulatory elements including: Exon or Intron Splicing 
Enhancers (ESE and ISE) and Exon or Intron Splicing Silencers (ESS and ISS) [6]. The 
exclusion or inclusion of genomic content in a transcript is governed by a ribonucleoprotein 
complex called Spliceosome through the process of splicing [6, 8]. Splice sites are present at 
each exon intron boundary, where during splicing introns are removed from pre-mRNA and the 
exons are then spliced together.  
Both spliceosome complexes composed of five small ribonucleoprotein particles (snRNPs) and 
auxiliary proteins are important components of the splicing machinery. The auxiliary elements 
and spliceosome complex function collectively to correctly identify the splice site. The initial 
stage of spliceosome complex assembly involves recognition of the 5` splice site by snRNP U1 
followed by binding of splicing factor 1 (SF1) to the branch point and binding of U2 auxiliary 
factor (U2AF) to both polypyrimidine tract and 3` terminal AG. This assembly of the complex is 
referred to as E-complex. The ribonucleoprotein U2 snRNP then binds to the branch point 
replacing the SF1and converting the complex to into an ATP-dependent complex: pre-
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spliceosomal A-complex. This complex is then converted to B-complex following the 
recruitment of U4/U6-U5 tri-snRNP. Conformational changes in the structure of B complex 
leads to the formation of catalytically active spliceosome “C complex” (Figure 1.2). Various 
mechanisms at different steps of spliceosome assembly can contribute in regulating an AS event. 
Few steps through which AS can be regulated are correct identification and selection of the 
splice site, U1 & U2 snRNP base pairing, transcription coupled AS, tissue-specific AS [9].  
 
Inhibiting Splice Site Recognition 
U1 snRNP are recruited to the 5` splice site, similarly U2AF complex and snRNP are also 
recruited towards the 3` splice site by the SR protein after binding with ESE. Domains 
containing Arg-Ser repeats (RS) mediate the interaction between SR proteins, ESE and protein 
targets. On the other hand, there are many means to evade the recognition of the splice site. For 
instance splicing silencers can block the access of snRNPs or other positive regulators, if they are 
present in close proximity of the splice sites or splicing enhancers. One such example is of 
polypyrimidine-tract binding protein (PTB) that inhibits the binding of U2AF to regulated exon 
by binding to polypyrimidine tract [10]. Activators are also blocked from binding to enhancers 
by the splicing inhibitors. Inhibitors such as FOX1 and FOX2 prevent the recognition of splice 
site by binding to exonic sequence, in close proximity of ESE, in pre-mRNA. This binding 
inhibits binding of other activators (TRA2 and SRp55) to the ESE, preventing the U2AF 
recruitment by the activators, thus inhibiting the formation of E-complex [11].  
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Figure 1.2: Basic principle of Splicing
1
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Reprinted by permission from Macmillan Publishers Ltd: NATURE REVIEWS | MOLECULAR CELL BIOLOGY 
[6], copyright (2005). 
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Splicing silencers, also inhibit splice site and reside 100-200 b.p. away from the enhancers. Such 
silencers are considered to function by assembling multimers along RNA, thereby causing splice 
site to become inaccessible [12]. It is also proposed that the protein-protein interaction between 
RNA-binding proteins residing in close proximity of alternative exon, causes the alternative 
exons to loop out, which inturn poses hindrances in further spliceosome assembly [13]. 
 
Protein Factors Regulating Alternative Splicing 
A functional spliceosome results from cross interaction between introns of U1 and U2 snRNPs. 
However, binding of hnRNP L to ESS can potentially inhibit the pairing of U1 and U2 
snRNPs15. An ATP-dependent spliceosome-like complex, known as A-like exon-definition 
complex (AEC) is very similar to A-complex and contains both U1 and U2 snRNP. The 
progression of this complex into the B complex is inhibited by hnRNP L-containing AEC in 
presence of hnRNP L, which functions by inhibiting the cross-intron complex formation between 
adjacent U1 and U2 snRNPs bound to exonic splice sites, resulting in exon-skipping. On the 
other hand, U4/U6–U5 tri-snRNP complex is recruited in absence of hnRNP L and after 
formation of A-like complex across exons, converting intron defined A complex to form the B 
complex. It is possible that hnRNP L hinders the formation of B-complex by either substantially 
shielding the interaction between the two snRNP or by introducing conformational changes in 
the mRNA. This change renders the mRNA unable to form cross-intron pairing between snRNP-
bound alternative exons.  
Though most of the studies have related inhibition of intron definition with splicing regulation, 
considering occurrence of AS due to activation of intron definition cannot be left out of the 
equation. A study conducted by Martinez-Contreras et al. (2006) [14] resulted in verification of 
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presence of hnRNP binding sites in close proximity of intron definition sites assist in splicing. 
Presence of hnRNP sites close to each other results in cross-intron interaction between hnRNP’s. 
This interaction causes the intron ends to come closer to each other. Thus, indicating that 
hnRNPs are indeed one of the probable explanations that promote splicing [15]. Proteins such as 
cis-acting elements also play significant role in splicing regulation, certain cis-acting elements 
control the binding at 5` splice site. Study conducted by Yu et al. (2008) [16] revealed presence 
of ESSs and ISSs that inhibit the recognition of proximal (strong) 5`splice site by selecting a 
weaker (distal) 5` splice site, thereby altering U1 and U2 snRNP pairing. The inability of splice 
factors to bind to the correct splice site is due to occurrence of conformational change in 
proximal 5` splice site complex by action of splicing silencers. As a result of which proximal 
splice site complex loses its edge over the distal splice site complex for binding to U2 snRNP 3` 
splice site complex [15]. 
 
Tissue Specific Alternative Splicing 
Numerous splice variants are produced from multi-exon genes subjected to AS. This AS also 
results in production of structurally and functionally distinct protein products. Understanding the 
principles governing the splicing differences has become a necessity. Even more alluring fact is 
that studies have shown presence of different isoforms from the same gene in different tissues 
suggesting involvement of different factors. Microarray techniques have played a huge role in 
determining tissue-specific regulation of AS events but can only provide us with a limited 
amount of information due to the inability to distinguish between closely related variants. In 
tissues, factors typical to tissues and regular RNA-binding factors act in combination, 
influencing spliceosome to regulate AS event. RNA map, provides a good understanding on the 
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effect of various factors on AS, based on the site of action [15, 17]. Expression of splice factors 
specific to tissues and regulation of mRNA’s (targeted by the splice factors) can contribute 
towards the understanding of tissue-specific AS [15]. Wang et al. (2008) [17] verified the 
differences in AS occurring in different tissues by taking into account ~105,000 AS events of 8 
different types. The results deduced from the analysis showed disparity between tissues in 
amount of splice variants produced. The isoforms detected to be differentially expressed between 
different tissues were also taken into account. The frequency of identified tissue-specific AS 
event through the analysis was approximated to be over 22,000. The conclusion deduced from 
the experiment indicated that most of the AS events are subjected to tissue-specific regulation 
[17]. 
Brain usually displays the most frequent number of splicing patterns, with several identified 
splicing regulatory factors. One of the splicing regulatory factors is nPTB, which is highly 
expressed in differentiated neurons. However, neural progenitor cells show high expression of 
PTB. Thus, presence of PTB-to-nPTB switch promotes the post transcriptional mechanism 
necessary for differentiating the neuronal cells. 
 
Impact Of Activators And Inhibitors 
Both splicing activators and inhibitors pose huge impact on the splicing procedures; a pre-
mRNA undergoes. The combinatorial, as well as the competitive effects of activators and 
inhibitors effect the inclusion or exclusion of an alternative exon in the transcript. However, it is 
the activity of particular regulator type that regulates the fate of alternative exon [18]. A study 
conducted by Crawford and Patton (2006) confirmed that different regulatory factors exclude or 
include an exon by competing to bind to the same element. It was shown that the competitive 
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struggle between SR proteins and hnRNPs for binding to the same element regulates the exon-2 
of α-tropomyosin [19]. 
 
Position Specific Splicing 
Different studies have concluded that occasionally it is the positioning of the auxiliary elements 
(ESE, ISE, ESS and ISS) and their binding proteins that regulate the exon. Depending on the 
location of the binding site relative to the exons, the proteins can function as both activators and 
repressors [20, 21]. NOVA1 binds to ESS residing in the exon-4 of its own mRNA, thus 
excluding the exon-4 [22]. On the other hand, the inclusion of exon-9 in pre-mRNA of GABA A 
receptor γ2 (Gabrg2) gene is promoted by binding of NOVA1 to ISE [23]. A study conducted by 
Ule J et al (2006) [24] focused on generating mRNA maps that contained locations for the 
binding sites of NOVA1 and NOVA2 and the significance of binding. The maps were developed 
by searching for the existence of YCAY clusters that are the binding sites of NOVA1 and 
NOVA2, and by utilizing prior information from mRNA’s targeted by the NOVA1 and NOVA2 
[24]. Hence, results clearly indicate that the positioning of the splicing regulatory elements and 
proteins with respect to the regulated exon is an important aspect that cannot be neglected while 
considering AS. Binding of factors responsible for splicing to enhancers or silencers brings forth 
structural changes in the mRNA, presenting or obstructing the access of splicing machinery to 
the splice sites of alternative exons [15]. 
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Involvement Of RNA In Alternative Splicing Regulation 
Secondary structures of pre-mRNA pose a substantial influence over the selection of splice site. 
It has been established that the secondary structures can affect splice sites by either binding 
competitively to splice factor binding sites or by masking the splice sites. Dscam mRNA in 
drosophila presents a complex alternative splicing event. Down syndrome cell adhesion molecule 
(Dscam) exon-6 cluster comprises of 48 mutually exclusive exons, in which pairing of conserved 
sequences, downstream of exon-5 (dock site) & upstream of every exon in exon-6 array (termed 
as ‘selector’ sequence) results in inclusion of one exon-6 variant in the transcript. Binding of 
hrp36 (selector sequence homolog) leads to exclusion of other exon-6 variants [15, 25].  
Riboswitches are part of mRNA molecules which effect gene activity by binding to the target 
genes. It is well established that riboswitches control gene expression in prokaryotes [26] and are 
involved in regulation of AS in some smaller eukaryotes. However, their involvement in AS 
event of higher organisms remains to be established. [27]. Small nucleolar RNAs (snoRNAs) 
have been associated with AS event regulation.  It was observed that AS is accomplished when 
snoRNA HBII 52 binds to the silencing element in exon Vb of serotonin receptor (5-HT2CR) to 
promote its inclusion [28]. 
 
Prediction Of Alternative Splicing 
Various bioinformatics approaches have been developed to predict AS events. Su et al. (2008) 
[29] developed an individual exon approach and Purdom et al. (2008) [30] used the residuals 
from probe level analysis to identify AEU on a per-sample level in the FIRMAGene package. In 
this approach, series of consecutive residuals that depart from 0 are considered evidence of AEU 
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events. The sample-level analysis challenges the detection of AEU events or the identification of 
common patterns across treatments or conditions. The limitations of this approach were 
overcome by the use of a linear model to compare the exon expression among groups (Laderas et 
al., 2011) [4]. However, group comparison is not suited to identify alternative exon usage 
associated with other conditions such as survival or time-to-event. In addition, the previous 
approach did not account for correlations between exons measured on the same sample. Cline et 
al. [31] formulated a ANalysis Of Splice VAriation ANOSVA approach that models the 
logarithm of the background corrected intensity (yij) as a function of two factors: concentration 
θj of the target mRNA in the sample (target concentration) and a probe affinity term φi relating 
changes in probe intensity to unit changes in target concentration (yij = φi + θj + error). 
However, a limitation is that the model is not applicable to a gene that produced more than one 
splice form [31]. Barash et al. (2010) [8] developed a probabilistic model that was able to 
identify AS signals specific to a particular condition by utilizing prior knowledge about the AS 
event such as (information corresponding to expression level correlation, effect of AS event and 
expected small number of AS signal) and dataset based specific knowledge including (levels of 
gene expression in dataset and measurement quality pertaining to the dataset) [8]. Shai et al 2006 
[32] developed a model namely Generative model for the Alternative Splicing Array (GenASAP) 
that predicts exon skipping event by quantifying splicing changes at single exon level. AS levels 
in microarray data are predicted by GenASAP, which utilizes Bayesian learning in an 
unsupervised probability model [32]. Studies conducted by Eisen et al. (1998) [33] applied 
clustering analysis to group genes by detecting similarities in patterns of gene expression. The 
same technique can be applied for identifying common patterns in AS events.  A matrix 
representing inclusion and exclusion isoform for each exon against specific condition can help in 
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identifying patterns pertaining to AS events [33, 34]. However there are many drawbacks to this 
technique, firstly it cannot account for tissue specific splicing. Also the clustering either 
distinguishes or neglects to distinguish between relative increase or decrease due to exon 
inclusion or exclusion [8]. Zheng et al. (2009) developed a Regression Method for AS detection 
(REMAS) that was based on the Lasso regression algorithm [35]. This approach assumes that the 
overall gene expression is strongly interrelated with the intensities of constitutive exons and an 
AS event results in altered gene expression. Thus, the difference between the expression of 
alternatively spliced and constitutive exon is considered as an indicator of AS. Finally, the 
Splicing Index (SI), a basic linear model for estimating changes of exon expression, applied in 
this model, ignores the relation between exons and identifies alternatively spliced exons 
individually [35]. 
A number of resources and databases have also been developed to provide and store information 
for correct prediction of AS event. Dralyuk et al. (2000) [36] developed Alternative splicing 
database (ASDB) using Genbank and SWISS-PROT annotation. This search engine allows 
queries to be searched across SWISS-PROT and GenBank fields and then simply following the 
links to all variants allows information regarding splicing event to be retrieved [36]. In 2001, an 
alternative splice database of mammals (AsMamDB) was developed by Hongkai et al. (2001) 
[37] to assist studies related to alternatively spliced genes of mammal. In AsMamDB 
alternatively spliced genes are associated with a cluster of nucleotide sequences. The main 
information provided by AsMamDB includes AS patterns, gene structures and also provides 
information about gene products and gene’s expression site [37]. Intron information system 
(ISIS) was developed to evaluate the function and evolution of spliceosomal introns in 
eukaryotes. Analysis through this system allowed recognition of many alternative spliced exons 
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[38]. HASDB, a database to detect AS events in human EST data was established by Modrek et 
al (2001) [39]. The results obtained through HASDB provide deep understanding of AS function 
in human genome [39]. Another bioinformatics resource for AS events ASD was initially 
developed by Thanaraj et al. and was upgraded by Stamm et al. (2006) and contains both 
manually and computationally generated data[40]. This resource functions by collecting and 
annotating data related to AS. This resource consists of various parts: AltSplice, AEdb and a 
Workbench. AltSplice is a database that includes computationally predicted alternatively spliced 
events, patterns and transcripts. Gene alignments are utilized by AltSplice to generate the data. 
Information on various features including splicing signals, SNP-mediated splicing, intra-specie 
homology and expression states is provided by AltSplice. Results obtained from this component 
indicated that about 61% of human genes undergo AS. It was also concluded that approx. 3.9 
alternatively spliced transcripts are produced form a single gene. Around 5200 orthologous gene 
pairs (between human and mouse) are included in AltSplice. AEdb is manually developed 
portion of ASD, it contains datasets that are based entirely on literature. It can further be divided 
into 4 components: AEdb-Sequence (searches pub-med for studies related to AS), AEdb-Function 
(provides with literature-based survey of functions related to a particular alternatively spliced 
exon. The functionalities of proteins generated as a result of AS event are divided into 11 
different categories), AEdb-Motif (provides with literature related to splicing regulatory motifs, 
intronic/exonic regulatory sequences and mutations. It reported some 153 and 81 enhancers and 
silencers respectively) and AEdb-Minigenes (provides graphical representation of splicing patters 
and regulatory sequences for all minigenes reported in literature and includes a collection of 82 
minigenes). The last component is a workbench that is used for analysis of splicing. This system 
allows retrieval of information on variety of aspects including intron characterization across 
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splicing signals, identification of splicing regulatory elements, prediction of putative exons and 
translation start codons [40]. Another database developed that accumulates lot of information 
regarding AS events is The Alternative Splicing and Transcript Diversity database (ASTD). 
ASTD comprises of vast collection of alternative transcripts that integrate transcription initiation, 
polyadenylation and splicing variant data. Alternative transcripts are derived from the mapping 
of transcribed sequences to the complete human, mouse and rat genomes using an extension of 
the computational pipeline developed for the ASD (Alternative Splicing Database) and ATD 
(Alternative Transcript Diversity) databases, which are now superseded by ASTD. ASTD 
datasets are established through three different categories of transcript-to-genome mapping. The 
three prediction categories include splicing (AltSplice), polyadenylation (AltTrans and AltPAS) 
and transcriptional start site (AltTSS) variant. Altsplice was used for predicting spliced isoforms 
and AS events by mapping EST and mRNA onto genomic sequences of Ensembl. ASTD 
contained 8,125,884 mapped transcripts for humans, 4,935,071 for mouse and 824,394 for rats. 
However, after removing all sorts of false positive transcripts, less than 25% of the true positive 
mapped transcripts remain in ASTD that can be used as supports for splice variants. Two 
components are involved in the polyadenylation: AltTrans and AltPAS, both are responsible for 
identifying polyadenylation but recognize sites corresponding to specific splice patterns and 
potential poly (A) sites irrespective of underlying splice patterns, respectively. Splice sites were 
included only if they met the specified criterion for internal priming, unmatched transcript ends 
and presence of polyadenylation signal that has already been reported. The Poly (A) sites 
obtained from both the components are then merged. The last component AltTSS was used for 
predicting transcription start site (TSS) using libraries of oligo-capped full-length cDNA’s. TSS 
were taken into consideration after aligning the sequences residing ~10,000 b.p. upstream of 
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each splice variant with NCBI Blast program. High-scoring sement pairs with minimum 95% 
identity were selected and onwards filtered with the specified criterion. Results provided by 
ASTD for human genome report 68% splicing variants, 68% transcription initiation variants and 
62% polyadenylation variants. 
Annotating genes, transcripts and proteins is a complex and difficult task. Tools that can 
correctly predict genes have become a requirement. AceView predicts gene models and provides 
with non-redundant and comprehensive graphical and sequence representation all public mRNAs 
by summarizing cDNA data from Refseq, GenBank and dbEST. Developed by NCBI, AceView 
utilizes heuristics for maintaining the same annotations. AceView is also displayed as one of 
UCSC gene tracks. Through analysis of the gene prediction tools, it was established that 
AceView transcripts are more close to Gencode as compared to other transcripts predicted by 
other tools. Therefore, for all transcripts AceView annotates the finest predicted CDS. Introns of 
both Gencode and AceView are common (except 10% and 14% specific to Gencode and 
AceView respectively), nucleotides used in spliced variants are common (except 8% and 12% 
specific to Gencode and AceView respectively). AceView also provides with a more efficient 
and simplistic method for annotating complete chromosome, while maintaining a similar 
annotation quality as to Gencode. One other feature provided by AceView is re-annotation of its 
mRNA with parsimonious Gencode-like CDS. Overall results indicated that gene structures 
predicted by AceView are in agreement with those of Gencode [41]. 
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Alternative Splicing Influences Health 
Alternative splicing has been associated with a variety of cellular, molecular and physiological 
functions. The regulation of these mechanisms by AS displays even more variability than their 
regulation through promoters [42]. Studies have concluded that AS is the causal agent of variety 
of diseases ranging from developmental regulation, cancer to apoptosis [43]. Numerous novel 
protein products with completely different peptide sequence, structure and functions are 
produced as a consequence of AS [43]. Alternative splicing affects most of the genes residing in 
the genome, and thus changes occurring during the transcriptional and translational processes 
might manifest in disease. The aberrant pre-mRNA processing might be instigated because of 
mutations in cis elements or altered expression of splicing factors and can potentially lead to 
tumoral transformations and cancer development [44]. Kim et al. established that aberrant 
mRNA and the resulting proteins have distinctive characteristics and properties that impart 
distinctive growth, differentiation and other molecular properties to the cancerous cells [45]. 
 
Alternative Splicing Necessary For Developmental Processes 
Occurrence of alternatively spliced events for generating genomic and proteomic diversity has 
been related to the proper functioning of many biological processes. Grabowski et al., (2001) 
[46] declared that AS was the primary cause of protein diversity required for proper functioning 
and development of the Nervous System (NS). The study suggest that AS of exon 21 residing in 
N-methyl-D-aspartate R1 (NmdaR1) receptor is responsible for many important regulatory 
processes in brain like neuronal development and synaptic plasticity. Other studies [47] 
conducted in 1995 concluded that C1 cassette exon containing NmdaR1 receptor mRNA can also 
be directed to function in plasma membrane. The mRNA isoform expression was inspected in 
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quail Qt6 fibroblasts cell line. The receptors were clustered on plasma membrane only when the 
gene contained C1 cassette exon. In absence of this cassette exon, the target protein was not 
observed in plasma membrane [46]. It has been established that C1 exon is required in gene to 
associate NmdaR1 receptor with the neurofilaments [48]. 
Wu et al. (2010) [49] demonstrated the importance of AS by associating it with complex 
biological system such as cellular apoptosis. Apoptotic pathway is initiated after interaction 
between specialized TNF family ligands with their receptors. Extracellular domains are 
proteolytically cleaved to generate soluble form of liquids [50]. As shown by Agarwal., 2003 
FasL variants are soluble and pose a significant influence upon apoptotic potential by blocking 
the death-promoting activity. These soluble isoforms of FasL, which are deficient of intracellular 
domain, transmembrane and portion of extracellular domains inhibit apoptosis and are generated 
due to AS event [51]. Another important gene is the Bcl-2 family, many members of this family 
have been associated with apoptosis inducing and inhibiting activity. Study concluded by Adam., 
2003 suggested that AS is involved in regulation of many Bcl-2 proteins. Bcl-x is a member of 
Bcl-2 family and is subjected to AS, producing two functionally separate isoforms: Bcl-xL and 
Bcl-xS. Bcl-xL is the longer transcript comprising of all four BH domains and functions by 
inhibiting apoptosis. On the other hand, produced as a result of AS, Bcl-xS is the smaller of the 
two transcript lacking both BH1 and BH2 domains. As opposed to the expression of Bcl-xL in 
long lived cells, expression of Bcl-xS is normally observed in cells enduring high turnover rate 
and in hormone-dependent tissues [50].  
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Alternative Splicing causes disease 
Different studies have displayed abnormal AS to be related with a variety of diseases. One of the 
diseases that manifests due to AS is the spinal muscular atrophy (SMA) that is characterized by 
the degeneration of alpha-motor neurons in brainstem and spinal cord. It affects approx. 1:10000 
infants world-wide. In most cases manifestation of the disease in infants leads to death in early 
childhood [52]. Aberrant assembly of snRNP is reported to cause SMA, this abnormal assembly 
occurs due to loss of Smn1 gene which is responsible for producing SMN protein [43]. The study 
conducted by Zhang et al. (2008) [53] showed that motor neurons remain the only ones that are 
affected by splicing, no other defects leading to cell death were observed due to splicing. Exon 
arrays were utilized to compare splicing difference between 3 normal and 3 Smn1deficient mice. 
The analysis concluded 259, 73 and 633 from spinal cord, brain and kidney respectively, to be 
significant at a false discovery rate (FDR) adjusted P-value < 0.1, while utilizing 200,000 probes 
that corresponded to exons of some 20,000 mouse genes. To confirm the results obtained, exon-
junction specific primers were designed to conduct real time RT-PCR on 31 genes that were 
displayed significant by the exon arrays. The results obtained from RT-PCR validated the exon 
array results with a rate of 97%, suggesting differential expression of the exons in a particular 
tissue. They also used 8 genes to confirm the expression of same exons across tissues. These 
findings revealed that different tissues possessed disparity in expression levels of the exons, 
indicating that the splicing alterations are tissue specific [53]. 
Familial Hypercholesterolemia (FH) is a metabolic disorder characterized by the presence of 
elevated levels of total cholesterol (TC) and low density lipoproteincholesterol (LDL-C) 
affecting cholesterol metabolism. In some cases patients suffering with FH display skin and 
tendon xanthomas, where FH manifests itself into premature coronary heart disease (CHD). 
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Mutations in three genes have been shown to cause hypercholesterolemia (HC) these are: Low 
Density Lipoprotein Receptor (Ldlr), Apolipoprotein-B (ApoB) and Pro-Protein Convertase 
Subtilisin like Kexin Type 9 (Pcsk9) [54]. However, primary cause of manifestation of HC is 
mutation in Ldlr. Zhu et al. (2007) [55] analyzed SNPs present in Ldlr relative to ESE matrices 
and discovered presence of C/T (ESE site) single nucleotide polymorphism (SNP) rs688 in exon-
12 of Ldlr that enhances splicing event resulting in exclusion of exon-12 from the transcript. Ldlr 
c-DNA from exon 10-14, from liver samples of 21 female and 22 male patients, was amplified to 
analyze the splicing event. Ldlr isoforms missing exon-12 were readily detected and genotyping 
of rs688 revealed presence of T allele (minor allele) and its presence decreases the splicing 
regulatory protein (Spr40) binding affinity, which recruits the splicing machinery, especially in 
pre-menopausal women (P-value<0.0042). Splicing pattern caused by SNP is significantly 
related to high cholesterol level in women only (P-value<0.024) [55]. A truncated receptor is 
generated as a result of Exon-12 skipping, this receptor is deficient of transmembrane domain. 
Thus, no internalization and membrane binding occurs preventing LDL uptake by the cell. 
LDLR also acts as a receptor for Apo lipoprotein E (ApoE), which is reported to be associated 
with development of Alzheimer's disease. Zou et al. (2008) [56] concluded that skipping of 
exon-12 in Ldlr transcripts increases the possibilities of occurrence of the disease in the male, 
while no association of splicing event with alzheimers was observed for women [43]. This 
tissue-specific AS can be held accountable for the disordered cell differentiation and signaling 
that contribute to stem cell like proliferation of cancer cells [57] . 
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Alternative Splicing Associated With Cancer 
Alternative splicing leads to formation and expression of numerous different transcripts, 
produced due to varying combinations of exon inclusion and/or exclusion. The translation of 
these transcripts may results in production of structurally different protein that also possess 
different functions [57]. Numerous studies have validated the presence of alternative splicing 
patterns in cancerous cells. Studies have also associated aberrant AS event with development of 
cancer. The variable expression of these AS or tumor-specific spliced variants triggers many 
cellular and molecular functions that promote proliferation, motility and division of cancerous 
cells [43]. Cancerous cells have been reported to disrupt the splicing patterns by two prominent 
methods involving somatic mutation in cis-elements and trans-acting factors involved in 
regulating splicing [58]. Mutations in trans-acting factors, on numerous occasions have been 
been reported to be associated with various cancers including glioma, ovarian and colon cancer. 
Additionally, many gene have been reported with normal splice variant that contributes towards 
the development of tumorigenesis [57]. However, the roles of spliced variants in cancer have not 
been fully established; presence of a spliced variant in malignant phenotype could be a 
coincidental i.e. the spliced variant could be present in the malignant phenotype without ever 
contributing to its development [43]. However, the fact remains that results obtained from both 
predicted and experimentally verified data claim that AS is more prevalent in cancerous cells. On 
the other hand, study conducted by Kim et al. (2008) confirmed presence of relatively lower 
degree of alternatively spliced exons in cancerous cells as compared to normal cells [45]. 
Breast cancer susceptibility gene (Brca1) has known association with development of hereditary 
breast and ovarian cancers and is also reported to produce several splice variant that might 
significantly contribute to the development of tumor. Occurrence of mutations in intronic splice 
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sites and degenerative sites, located near intron/exon boundary, result in development of 
numerous splice variants. One such splice variant, resulting in exclusion of the constitutive exon-
18, involves G>T mutation at position 6 of exon-18, leading to E1694X change and removal of 
26 amino acids (a.a).The mutation disrupts the C-terminus of BRCA1. It was hypothesized that 
the mutation in consideration disrupted the ESE. However, the mutation occurred in a region not 
rich in purines whereas ESE’s are normally expected to be residing in purine-rich region. 
Utilizing motif scoring matrices it was established that the mutation disrupts ESE due to 
confirmation of correlation between SF2/ASF high-score motif distribution and the splicing 
patterns. Thus, SF2/ASF recognition sequence is a necessary; absence of recognition sequence 
can lead to skipping of exon-18 [59]. 
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Glioblastoma Multiforme 
Background 
Appropriate neuronal cell differentiation is necessary for the proper functioning of brain cells. 
Misregulation in neurotransmitter signaling, sequence mutations, methylation patterns, copy 
number variation, faulty apoptosis, erroneous DNA repair and cell differentiation can result in 
stem cell like proliferation of cells leading to development of brain malignancies [57].  
The World Health Organization (WHO) has grouped brain cancers into four different groups (I, 
II, III and IV) based on the severity of the disease, where group IV represents the most malignant 
tumors. Glioblastoma Multiforme (GBM) is considered as one of the primary and highly 
aggressive brain tumors, accounting for 50% of all CNS malignancies, 20% intracranial tumors 
[60] and 90% of all glioblastoma. GBM usually forms in cerebral white matter, exhibits 
devastating consequences with average survival ranging up to approximately 12 months and has 
been placed in group IV by WHO, due to high capacity of GBM to proliferate in the brain [61]. 
Secondary GBM referred to as ‘Astrocytoma’, display slow progression, accounts for less than 
10% of all GBM cases and occurs in relatively younger patient.  
The average survival time for a patient suffering with glioblastoma was estimated to be around 
five months. Increased time period after manifestation of disease resulted in decreased survival 
rates (42.4% at 6 months, 17.7% at 12 months and 3.3% at 24 months). It was also determined 
that males are slightly more susceptible to primary glioblatoma than females with male to female 
ratio being 1.28 [62]. However, females are more susceptible to secondary glioblastoma. 
Furthermore, age of an individual also poses significant effect over survival. Older age at 
diagnosis reduces the survival rates, while patients with age less than 50 years showed 
significantly longer survival and show higher incidence of rare secondary glioblastoma. 
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Manifestation of of primary tumors is observed in majority of older patients diagnosed with 
GBM [63]. Johnson et al. (2011) concluded that treatment of GBM patients with radiation and 
drug therapy increases the survival from 12 to 15.6 months [64]. However, even with all the 
therapies provided, GBM still displays high resistance to treatment because of presence of small 
areas displaying necrosis and hemorrhage in the tissues [65]. Studies also confirmed that 
ethnicity also contribute significantly in GBM development. It was estimated that white people 
are more likely to develop brain tumors as compared to non-white people [66]. 
 
Genes And Gene Expression Associated With Glioblastoma Multiforme 
In most of the GBM cases, aberrant genomic alterations are associated with the development of 
tumorous cells. Therefore, understanding the involvement of underlying genes, pathways, 
mechanisms and functions that contribute towards the development of brain malignancies is a 
must [65]. Various genes including Egf, Nf1, Idh1 have been associated with the initiation and 
progression of GBM [67]. 
Transcription is promoted by activation of several tyrosine kinases and downstream signal 
molecules after binding between epidermal growth factor (Egf) and epidermal growth factor 
receptor (Egfr). This binding also results in dimerization of Erg receptor family (Erb 1-4) [68]. 
Studies confirmed association of polymorphism, 61 A/G, with poor survival in GBM [69]. 
Another study performed tagging of Egf to estimate effect on the development of GBM. Results 
indicated minor alleles of four polymorphic events, rs17238095, rs3796944, rs9992755 and 
rs11568994 located in different exons, to be significantly associated with the GBM [68]. 
Therefore, analysis of various studies relates higher expression of Egf to be associated with 
GBM. 
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Neurofibrin1 (Nf1) is another gene that is negatively associated with GBM, by acting as a GBM 
suppressor gene. Accumulation of 19 specific mutations (6 non-sense, 4 splice site, 5 missense 
and 4 frame-shift indels) was observed and it was predicted that these mutations are responsible 
for the probable inactivate the gene. In all it was estimated that somatic mutation manifested in 
23% of the total patients were contributing towards the inactivation of the gene and in the 
process confirming the significant association to GBM [65]. 
Isocitrate dehydrogenase 1 (Idh1) is a gene residing in chromosome-2 and has been associated 
with secondary glioblastoma [70]. IDH1 is responsible for the production of NADPH by acting 
as a catalyst in the formation of α-ketoglutarate from isocitrate through the process of oxidative 
carboxylation. Experiments conducted showed that mutations in Idh1 reduced the activity of 
enzyme IDH1 due to formation of heterodimers that are catalytically inactive. This process also 
results in upregulation of a transcription factor hypoxia-inducible factor subunit (Hif-1a), which 
is reported to be associated with tumor growth [71]. The frequency of mutation of Idh1 was 
estimated to be above 80% in most of gliomas except primary GBM, which exhibits reduced 
frequency of less than 5% [70]. 
 
Genetic Pathways 
Due to development of various techniques and methods, understanding of genetics underlying 
glioma development has greatly improved. Large scale sequencing of genome has led to 
detection of several novel genetic alterations and pathways, adding valuable information towards 
further understanding glioma and may also help in identification of targets for interventions [70]. 
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Receptors (such as EGFR etc) normally reside in inactive state and get activated after binding to 
their respective ligands (EGF). Higher expression of Egfr is associated with development of 
primary GBM, where 70%-90% of GBM cases showing upregulation of Egfr also possess 
amplification of Egfr sequence. The interaction between EGFR and EGF results in recruitment of 
phosphatidylinositol 3-kinase (PI3K) complex composed of two subunits: catalytically active 
protein p110α and regulatory protein p85α. PI3K ultimately leads to activation of mammalian 
target of rapamycin (mTOR), a downstream effector molecule, by phosphorylation of 
phosphatidynositol-4,5-biphosphate (PIP2) to phosphatidynositol-4,5-3-phophate (PIP3). This 
entire process results in inhibition of apoptosis and consequentially promoting cell proliferation 
and survival. Phosphatase, tensin homologue, deleted on chromosome TEN (Pten) is a tumor 
suppressor gene that inhibits the cell proliferating action of PIP3. About 40% of the primary 
GBM cases exhibit mutation in Pten. The Cancer Genome Atlas (TCGA) pilot project reported 
alteration of Egfr/Ras/Nf1/Pten/Pi3k pathway in 88% of the GBM cases [15, 70]. 
Tumor protein p53 (Tp53) encodes for p53 protein that is reported to be associated with a variety 
of malignancies. Its main function is to regulate cells in response to increased cellular stress, cell 
death, differentiation. High levels of p53 protein are normally observed in malignant and 
transformed cells. It mainly consists of three domains including DNA-binding, transcription 
activation and oligomerization domains. The p53 protein is a DNA-binding protein which 
activates in response to DNA damage. Transcription of p21, Mdm2 gene is induced by activated 
Tp53. Amplification of Mdm2 is associated with ~15% of glioma cases, binds to Tp53, thereby 
blocking transcriptional event induced by action of Tp53. Another gene p14ARF binds to Mdm2, 
blocking the Tp53 binding ability of Mdm2. Methylation in promoter region of p14ARF is 
observed in almost 50% of glioma cases. Tp53 is also responsible for regulating p14ARF thereby 
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acting as a feedback mechanism. Another gene Mdm4 regulates the activity of Tp53. Thus 
mutation resulting in altered function of Tp53 can completely disrupt the pathways involving 
Tp53, Mdm2, Mdm4 and p14ARF. Different studies have reported frequency of mutated Tp53 in 
primary glioma (65%) to be reduced than its presence in secondary glioma (28%). The Cancer 
Genome Atlas (TCGA) pilot project also reported alteration of Tp53/Mdm2/ Mdm4/ p14ARF 
pathway in 88% of the glioblastoma cases [15, 70]. 
 
Alternative Splicing Associated With Glioblastoma 
Different studies to enumerate the expression of genes and their isoforms across tissues have 
been carried out. Ramskold et al., (2009) established that brain tissues contain expression of a 
large number of genes and gene isoforms because of high frequency of AS events [72]. AS is a 
natural process adopted by the genome to produce genetic and proteomic variation [4]. However, 
misregulation of AS has been associated with development of many diseases and cancers [59]. 
The development of GBM has also been linked with alternative splicing of various genes. One 
such gene is glioma-associated oncogene homologue 1 (Gli1), which is zinc-finger transcription 
factor. Gli1 protein functions as nuclear mediator for Hedgehog signaling pathway, a pathway 
known to regulate genes involved in premature development of the CNS and observed to be 
activated in gliomas. After being released from cytoplasm, Gli1 translocates to cell nucleus 
where its binding to GLI1-binding elements activates them. Lo et al., 2009 reported a presence of 
a truncated splice variant of GLI1 (tGLI1). The new variant manifested in most GBM cells but 
was undetectable in normal brain cells. Further investigation of tGLI1, established that the 
variant is produced due to deletion of 123 bases from exon-3 and exon-4. The in-frame deleted 
portion contains 41 codons corresponding to specific amino acid residue position (34 to 74) in 
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the protein. Production of the variant tGLI1 upregulates CD24, a gene reported to be associated 
with increased invasiveness. The results suggest that production of tGLI1 results in gain-of-
function that relates to aggressiveness of GBM cells due increased invasive and migrating 
properties of the infected cells [73]. 
Izaguirre et al. (2011) associated AS in (Usp5) with GBM. Usp5 also referred as isopeptidase T 
is regulated by polypyrimidine tract-binding protein 1 (Ptbp1), whose upregulated expression 
level is responsible for cell proliferation and migration in GBM cells. PTBP1 protein is a splicing 
regulator and its members are responsible for repressing the recognition of exons during splicing, 
exon inclusion, replication, mRNA stability, RNA transport and viral translation. AS of Usp5 
leads to the formation of two isoforms: isoform-1 formed due to inclusion and isoform-2 
containing exclusion of exons. This variation is observed as a result of 69 bases altering exon-15. 
Study revealed expression Usp5 isoform-1 to be significantly correlated to Ptbp1 expression. 
Results obtained were confirmed with RT-PCR and associated expression Usp5 isoform-1 with 
reduced PTBP1 levels. Invitro studies also confirmed the presence of consensus PTBP-binding 
sequences in proximity of alternative exon. Thus, for isoform-1 presence of binding site specific 
to PTBP1 was observed at 5` splice site, resulting in exclusion of exon from isoform-1. Increase 
in the levels of Usp5 isoform was negatively correlated to GBM cells migration and proliferation 
[74]. 
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Analysis Of Microarray Gene Expression 
Understanding of genomic variations and differences in gene expression levels related to a 
specific phenotype requires knowledge of the underlying genes and pathways [75]. Transcription 
and translation of the gene into mRNA and protein respectively is an extremely complex and 
delicate process involving many regulatory factors [76]. Therefore, quantifying mRNA 
expression levels pertaining to specific phenotype is necessary for identifying its impact on the 
phenotype. 
 
Gene Expression Measuring Platforms 
Genetic makeup, environmental conditions, cellular response and regulatory factors all 
contribute to and are responsible for varying expression levels of the genes. These expressions 
levels are quantifiable through utilization of various techniques, particularly developed to 
measure gene expression over last two decades [77]. Most prominent methods used to quantify 
mRNA levels include Northern Blot [78], real time polymerase chain reaction (RT-PCR) [79], 
microarrays [80] and RNA-seq [81]. 
Northern blotting is a technique derived from southern blotting, in which enzyme-cleaved DNA 
fragments, separated due to movement of ions from positive to negative electrode are transferred 
to nitrocellulose strips. In northern blotting, single strands of DNA are coupled covalently to 
paper and are transferred through a gel. After which hybridization with labeled 32p probe is 
performed to correctly identify and detect specific sequence [78]. 
Microarray is a high throughput technique that was developed in the recent past and has the 
capability of measuring expression of thousands of gene in chorus. Microarrays utilize the 
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information obtained from mRNA and on assembly basis can be divided into two categories: 
spotted microarrays and oligonucleotide microarrays [80]. Through this methodology, manual 
arrays are developed that takes into consideration both research interests and cost limitation of 
the experiment. However, the results obtained through this technique are not very consistent 
[82]. On the other hand, oligonucleotide microarrays consist of arrays in which probes that are 
formed by adding each base individually. Additionally, much of the research being conducted 
globally nowadays utilizes oligonucleotide microarrays developed by different companies [80]. 
There are three main microarrays platforms that have been widely utilized for expression studies: 
two-dye approach, BeadChips and Affymetrix. The working of these microarray techniques is 
very identical. First step involves the hybridization of the labeled sample to the DNA probe, after 
the samples are applied onto the array. The complete process is affected by a variety of external 
and environmental factors including temperature, salt concentration, etc. The previous step is 
followed with washing of the array to ensure that hybridized targets are the only ones that remain 
attached onto the microarray. Thus washing greatly reduces the chance of cross-hybridization. 
Next step involves measuring the intensity of the fluorescence emitted from the slide. This is 
accomplished by placing the slides in a scanner, allowing the scanner to measure the intensity of 
fluorescence emitted after being excited by the laser. After which the final step involves the 
measurement of gene expression levels [83].  
In two-dye microarray, fluorophore dye labeled both target gene samples are hybridized to the 
same array. Normally, Cy3 (fluorescence at red wavelength) and Cy5 (fluorescence at green 
wavelength) dyes are used to label the samples. Comparing the intensities of the fluorescence 
emitted by each wavelength in the array determines comparative expression levels between the 
samples of interest . Therefore this method offers reduced variability by performing direct 
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comparison between two samples [84]. In the same manner, one-dye platforms utilize 
fluorescence to label the samples but in this case only one dye is used. In this both the samples 
are placed in different arrays and expression level of each sample is determined by measuring the 
fluorescence [83]. One-dye systems present a very simplistic and flexible method to compare 
results between various groups of samples [80]. 
BeadChip microarray is designed by Illumina BeadArray Technology. The arrays designed 
comprise of thousands of 50mer oligonucleotide arranged in a unique bead type structure that are 
assembled into the microwells fixed onto surface of the BeadChip. Alongside expression 
measurement BeadChips can be used effectively for genotyping also. Different techniques can be 
utilized to synthesize probes of varying length: short (25-30 bases) and long (50-80 bases). An 
array contains approximately 30 instances of each bead type [85]. 
 
Affymetrix Gene And Exon Platform 
Among all the microarray techniques available in the market, Affymetrix platform is the one 
most extensively accepted and utilized microarray technology. Manufactured by utilizing the 
process of photolithography and combinatorial chemistry, each GeneChip presents some 1.4 
million individual oligonucleotide probes. The advantageous property of the spots on GeneChip 
is that each spot can contain millions of oligonucleotide copies [104]. Repeated illumination is 
performed to synthesize the probes onto the glass substrate. The glass substrate is layered with 
linkers, containing photoliable protecting groups. Normally, probe sets representing the genes or 
mRNAs of interest are 11-20 25mer oligonucleotide probe pairs. Based on the thier 
characteristics probe pairs are divided into two categories: perfect match (PM) probe and 
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mismatch (MM) probe (including modification on the 13
th
 base) accounting for removal of non-
specific hybridization and background noise [86]. 
Affymetrix gene array platform was designed to quantify the expression levels of well annotated 
genes obtained from any tissue. The probe set utilized for quantifying the expression levels of the 
gene consist of multiple probes that are complementary to different locations of the genomic 
locus. This platform contains 764,885 25-mer distinct probes that allow cross-examination of 
expression levels across 28,869 genes, based on March 2006 (UCSC hg18, NCBI Build 36). On 
average each gene contains 26 probes spanning different regions of the gene. This platform 
provides with an accurate and robust approach to detect transcriptional activities of genes [105]. 
GeneChip® Human Exon 1.0 ST Array is the latest platform developed by the Affymetrix for 
interrogating expression of genes at exon level [87]. The main objective behind developing exon 
array was “in interrogate each potential exon with one probe set over the entire genome on a 
single array”. The exon array platform consists of more than 1.4 million probe sets, where on 
average each probesets consists of 4 probes, built using human genome assembly (July 2003, 
hg16, build 34) [106]. The probe sets corresponds to 1,796,124 probe selection region (PSR) 
from 1,084,639 exon clusters and more than 24,000 genes in human genome. Different 
annotation were used to support probe sets, 50% probe sets are based on single type annotation 
where half were derived from EST’s and the other half from GENSCAN. The advantage of using 
exon array platform is that it allows detection of transcript diversity over a wide range. Using 
splice junction, detection of a small variation involving shift of 3 b.p. in splice sites becomes 
possible. However, this array platform as yet does not support exon junctions due to limited 
understanding of the variants present in the transcripts [106]. Increased probe concentration 
increases the density of probes four times and an eight-fold increase in perfect matches, as 
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compared to the previous platforms. Exon array utilizes specific probes instead of MM probes 
for detecting hybridization due to pure background. All these reformed advancements result in 
increased genomic coverage that provide with better estimation of gene-level expression analysis 
& also help to detect novel transcript variants due differences in exon-level expression [87].  
 
Data Processing And Normalization 
Processing of raw gene expression data obtained from any technique with an image analysis 
program is essential, as the initial data obtained is in form of scanned images. The processing of 
fluorescence emitted by probe in the array along with transformation of data need to be 
performed prior to applying statistical analyses on the data. The science behind normalization is 
to adjust for the variability encountered due to differences in microarray techniques and to 
reduce the background noise [88]. Signals emitting fluorescence are produced from the 
GeneChips during hybridization. The raw data from these signals is stored in a DAT extension 
file [89]. Information pertaining to image, pixels and technical information from the complete 
experiment is contained in the raw data. After performing grid alignment for registering set of 
unevenly spaced, parallel and perpendicular lines and computation of 75
th
 percentile of the spot 
specific pixel intensity, estimated intensities specific to each spot are stored in a CEL extension 
file. Since all the information present in DAT file is summarized to CEL file, grid alignment 
becomes an important step for avoiding errors and correctly summarizing information from DAT 
to CEL file. Additionally, image quality is affected by many other factors like flagging and 
background variations [89]. Another aspect that poses a significant affect over the quality of the 
image resulting in production of blurry images is the pixel in high intensity parts. These affect 
the reading of neighboring pixels possessing lower signals by recording the intensities from 
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different pixels. Non-specific hybridization due to MM probe also contributes to array’s cell 
signal intensity. Therefore, to have more accurate estimate of cell-hybridization, background 
signals are subtracted. Similarly flagged features, bad features (higher pixel SD), negative 
feature (higher background compared to foreground) and dark feature (extremely low signal) all 
need to be removed manually or through computational means from the data [80]. 
Variations such as microarray manufacturing process, biological sample preparation and 
intensity measurements affect the data analysis. Therefore, normalization of the probe intensity 
data is performed which takes into account variations produced due to systemic errors and bias 
originating from microarrays and attempts at reducing the affect instilled by these variations 
[90]. Numerous statistical approaches to normalize the expression data have been proposed: 
Affymetrix Microarray Suite MAS5.0 software, Robust Multi-array Average (RMA) [91, 115] 
and GeneChip RMA (GCRMA) [92] are some widely used methods. 
MAS5.0 utilizes intensity values of PMij and MMij, of the ith array and jth probe, to reduce the 
overall background noise. Implementation of log-transformation in the methods is responsible 
for reducing the reliance of variance on mean. The outliers are accommodated by the usage of 
Tukey’s biweight function (Tbi) [91, 92]. Another method developed for normalization of data is 
RMA, which was mainly developed to overcome issues related to MM, as RMA considers 
information related to MM as biologically and statistically insignificant. Thus MM probes are 
not considered and PMij intensities are stated as T(PMij). The values are transformed by applying 
background corrections, normalization and applying logarithm [91]. To the background-
corrected PM intensities base 2 logarithm is applied and substitution of original values is 
accomplished through utilization of mean quantile. This quantile normalization is performed at 
probe level, where the probe intensities for each array in array sets are distributed in similar 
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manner. Another normalization technique that is more extensively used by the scientific 
community is GCRMA. It is very much similar to RMA with the exception that it takes probe 
sequence into consideration, uses a different background correction and uses. Probe sequence 
consideration by GCRMA allows for intensity adjustment of probes showing different log 
intensities due to variation in GC content of the probes [92]. Thus PM values are corrected based 
on both GC content and MM probes, allowing GCRMA to have increased accuracy to estimate 
specific probe binding [92].  
Comparison between the three techniques has established that GCRMA normalization method 
outshines the other two normalization techniques and RMA yield more promising results than 
MAS5.0 [92]. 
 
Identification Of Differential Expression Using Linear Models 
General Linear Model (GLM) is one of the most commonly employed statistical models in the 
fields of social sciences and quantitative biology and comprises most of statistical analysis 
including the t-test, Analysis of Variance (ANOVA), Analysis of Covariance (ANCOVA), 
regression analysis, and many of the multivariate methods including factor analysis, cluster 
analysis, multidimensional scaling, discriminant function analysis, canonical correlation, and 
others. GLM describes the relationship between variables of interest by approximating to an 
optimal solution. The two variable case is the most simplistic type of GLM, consisting of 
explanatory and response variables.  
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Figure 1.3: Bivariate plot 
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Considering an example of tumor suppressor gene, looking at the plot it is expected that a 
positive relationship exists between the two variables with an increase in gene expression 
expected as the survival increases. How can we model this relationship so that we are able to 
describe the effect of survival accurately for any given sets of genes? The answer lies in the 
GLM approach which takes into account the effect of survival (X or explanatory variable) over 
gene expression (Y or response variable) and models this effect by fitting a line: 
y = b0 + bx + e 
y = a set of outcome variables 
x = a set of pre-program variables or covariates 
b0 = the set of intercepts (value of each y when each x=0) 
b = a set of coefficients, one each for each x 
We begin by collecting data for a number of individuals with varying survival periods. These 
individuals are called the experimental units. We plot the data into two-dimensional space and 
observe that both survival and gene expression are positively correlated. Now, we can draw a 
line that explains the ‘general’ effect of X over Y.  By general, we mean that with a unit increase 
in X, we expect some units increase (or decrease) in Y. This quantity is called as the ‘slope’ of 
the fitted line. Because we are able to draw a ‘linear’ line (not a curve or any other shape), this 
generalization is referred to as the General Linear Model. The important point is that the effects 
of any sets of variables can be modeled quite precisely if we can fit a linear line that describes 
the relationship between the variables truthfully. It is not expected that all the points would fall 
directly onto the line. Usually, there will be scattering of data points around the fitted line 
(Figure 1.3). This realization is true because not every individual will have the same gene 
expression at any given time point. This scattering explains another important term in the GLM, 
which is the ‘error’ (e) term or the deviation of the experimental units around the mean. Ideally, 
we would like to minimize the experimental error and the line that best fits the data (with 
38 
 
minimum scattering) is the linear model for the given data. This additional error term in the 
GLM proves useful for explaining the variability in the data set and also tests whether a more 
complex model is needed or not (quadratic or cubic relationship). Model specification is an 
important step for correctly answering the research question and selection of insignificant 
variables can instill biasness in estimates of coefficients [103]. 
 
Functional Analysis 
Gene expression patterns across thousands of genes results in production of tremendous amount 
of data which then needs to be analyzed to identify genes that are calculated to be significantly 
associated to the conditions under consideration. Various public databases, after being provided 
with gene list, categorize genes and gene products by including them into specific categories and 
sub-categories. These databases detect the genomic and functional categories enriched in the 
genelist provided, through help of statistical tools embedded in the database system [93]. Two 
such databases that are of high significance in biological community include Gene Ontology 
(GO) (http://www.geneontology.org/) and Kyoto Encyclopedia of Genes and Genomes (KEGG) 
(http://www.genome.jp/kegg/pathway.html). Developed in 1998, the main objective of Gene 
ontology (GO) consortium was development of a system that provided a unified procedure to 
impart vocabulary to all novel findings even as knowledge of genes and proteins for all 
eukaryotic cells is accumulating and changing [94, 95]. Initially, GO contained information 
database against three model organism including mouse, yeast and fly. However, presently GO 
consortium constitutes major repositories microbial, plant and animal kingdoms genomes. GO 
web based tool contains diverse description on three categories including cellular component, 
molecular function and biological processes, where description in the sets is called ‘term’ [96]. 
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The cellular category of GO consortium mainly deals with the exact location of gene product 
within a cell. The biochemical properties and activities related to genes are represented by 
molecular functions. A broad variety of functions both simple and complex are included in 
molecular function category. Lastly, biological objectives referring to processes including or 
leading to chemical and physical alterations of genes and their products are included in 
biological processes. 
KEGG database is an online public resource containing information from 19 different databases 
on system, genomics and chemical properties across several genes and gene products. System 
information, one of three main categories, represents the functionality of any biological system. 
The second category, “Genomic information” represents the genomic building blocks of life 
while Chemical information represents the chemical building blocks necessary for life [97]. The 
graphic tool embedded in the KEGG database system allows retrieval of information pertaining 
to molecular networks and cellular processes. The graphic tool illustrates many metabolic 
interaction networks, genetic and environmental information processing, chemical structure 
transformation network and human diseases. The pathway maps, representing a particular 
network are described through nodes (genes, proteins) and edges (relation, reaction). 
Computational and statistical analysis conducted on large scale genomic data results in formation 
of genelist that includes genes found to be significantly associated with the characteristic of 
interest. Making biological inferences from the significant genes requires functional 
categorization of these genes in groups based on some specific pattern. Over the years some 68 
reputable bioinformatics tools have been developed that take into consideration biological 
information accumulated in various public databases (GO, KEGG). Utilizing these tools allows 
systematic assembly of enriched functions and pathways corresponding to the significant genes 
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[98]. Some of these high-throughput enrichment tools include Onto-Express, MAPPFinder, 
GoMiner, DAVID, EASE, GeneMerge and FuncAssociate that extract relevant GO terms and 
KEGG pathways from several databases. One of these online resources Database 
for Annotation, Visualization and Integrated Discovery (http://david.abcc.ncifcrf.gov/) (DAVID) 
is a highly reputable functional enrichment tool, which amalgamates/accumulates various 
features including back-end annotation database, advanced enrichment algorithm and powerful 
exploratory data mining ability within itself. DAVID utilizes information from several databases 
to extract GO terms and KEGG pathways, Fischer’s Exact test is then performed to categorize 
the genelists [99]. Thus enrichment analysis provides valuable information related to gene 
ontologies and pathways for the genelist provided. 
Transcriptome variants produced due to alternative exon usage (AEU) are an important aspect of 
gene regulation. Almost 90 % of the multi-exon genes in humans are transcribed into multiple 
transcript variants as result of alternative mRNA splicing [100]. Alternative exon usage has been 
associated with proliferation of malignant cells in humans [57, 101]. Glioblastoma multiforme 
(GBM) is the most severe form of malignant brain tumors and the expression of numerous genes 
has been associated with this cancer [62]. These transcripts might be related to a specific 
metastatic phenotype and can potentially function as diagnostic and prognostic biomarkers and 
even as therapeutic drug targets [102]. However, few consistent gene expression biomarkers of 
GBM have been reported [57]. Two reasons for this are the limited consideration of AEU and, 
the analytical approaches typically used to study AEU that ignore the relationship between exons 
within a gene. The goals of this study are to develop a general hierarchical model to identify the 
differential associations between cancer survival and expression at a gene or exon level that 
indicate AEU and to apply this methodology to identify biomarkers of GBM survival. 
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CHAPTER 2 
RESEARCH PAPER 
Background 
Alternative splicing (AS) is characterized by the formation of different mRNA isoforms as a 
result of including or excluding different exonic or intronic segments. This process is responsible 
for generating protein diversity [1-3]. AS can be divided into three broad categories; intron 
retention, cryptic splice site usage (functions by elongating or shortening the exon), and 
alternative exon usage (AEU) or exon skipping. AEU includes cassette exons (discrete exons that 
can be independently included or excluded) and mutually exclusive splicing (which involves the 
selection of one from a group of exon variants) [3]. Approximately 75% of multi-exon genes 
exhibit AS in humans [4] and on average more than 3 alternative transcripts are mapped to a 
gene [5]. The identification of "exon-level" expression profiles and characterization of AS events 
has become possible with the availability of exon platforms (e.g. GeneChip Exon Array).  
The brain exhibits particularly high rates of AS [6] and the highest number of AEU events [7]. 
Regulation of gene expression due to splicing has been associated with cancer. Many AEU 
events have been associated with disordered cell differentiation and signaling that contribute to 
stem cell like proliferation of cancer cells [8].  
Glioblastoma multiforme (GBM) is an aggressive type of brain cancer and the role of genes and 
AEU on GBM survival is still not completely understood [9-11]. Most work on AS and GBM 
studied individual genes or compared AS between GBM and control (e.g. blood) samples. The 
relationship between AS and the survival of individuals diagnosed with GBM has not been 
studied. Understanding of the factors influencing survival is particularly important in GBM 
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because the average survival after diagnostic is approximately one year [12, 13]. Furthermore, 
several epidemiological factors influence GBM survival including gender, race and treatment 
[14]. Thus, a more accurate understanding of the relationship between AS and GBM survival 
must consider epidemiological factors and inter-individual variability. 
Several approaches to identify AS events have been proposed. However, most approaches have 
limitations that can bias the identification and characterization of AEU.  For example, Su et al. 
developed an individual exon approach [15] that does not model the covariation between exons 
within a gene. Purdom et al. used the residuals from probe level analysis to identify AEU on a 
per-sample level [16]. The sample-level analysis challenges the detection of AEU events or the 
identification of common patterns across patients receiving the same treatment or from the same 
epidemiological strata. Laderas et al. and Zheng et al. proposed group comparison using linear 
models to overcome the limitations of the previous approach [3, 17]. However, group 
comparison is not suited to identify AEU associated with other conditions such as survival or 
time-to-event. In addition, the previous implementation does not account for correlations 
between exons measured on the same sample. Cline et al. formulated a ANalysis Of Splice 
VAriation ANOSVA approach that cannot be used in gene that produced more than one splice 
form [18].  
The goal of this study is to implement an exon-based and gene-centric model that allows the 
detection of AEU associated with cancer survival. The approach addresses the limitations of 
previous approaches by modeling the exon-level expression profiles within gene from all 
samples across all treatments or conditions studied. Our approach accommodates the 
dependencies between exons within a gene and patient and allows testing the hypothesis of 
differential exon expression or usage between treatment groups. A unique advantage of our 
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flexible approach is that one model encompasses all scenarios: i) multi-exon genes that have 
AEU, ii) multi-exon genes that do not have AEU, and iii) single-exon genes. This novel 
approach was applied to the identification of AEU associated with GBM survival. The 
performance of the approach and accuracy of the results were assessed by using separate training 
and validation data sets. Gene set enrichment and gene functional analyses offered insights into 
the biological processes related to the AEU genes associated with survival. Results were mapped 
to genes and to known or predicted AS events to further confirm and add biological 
interpretation to the results of our model.   
 
Materials and Methods 
Training Dataset 
Survival, clinical and exon expression information from 250 patients diagnosed with GBM was 
obtained from The Cancer Genome Atlas (http://cancergenome.nih.gov/) repository (May 2011 
data freeze). Surgical samples had a minimum of 80% tumor nuclei and maximum of 50% 
necrosis. In this training data set, clinical or epidemiological variables considered in the analysis 
of exon expression included treatment (levels: chemo-radiation-targeted or CRT, chemo-
radiation-non targeted or CRnT, radiation or R, other therapies or OTHER or no therapy or 
NONE); racial ethnicity (white Caucasian and others); and gender (male and female). These 
clinical factors were accounted for in the model because of their known association with survival 
[9]. The survival variable associated with exon expression was the time from diagnosis to death 
(expressed in months). 
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Exon expression measurements from each patient were obtained using the 
AffymetrixGeneChip® Human Exon 1.0 ST Array. Platform details can be found at 
(http://www.affymetrix.com/support/technical/annotationfilesmain.affx) (Affymetrix, Inc., 
2012). Briefly, this platform includes information from 1432143 (1.4 million) probe sets 
representing known and predicted exons on both strands of the genome. These probe sets were 
mapped to more than 25000 genes. Array platform and data was log-2 transformed and 
normalized using quantile and RMA normalization at the probe level following the procedures 
described in Beehive (http://stagbeetle.animal.uiuc.edu/Beehive). Probes sets within exon were 
collapsed using a Tukey biweight function that provides an iterative reweighed measure of 
central tendency. This robust statistic provides a single exon expression that is not heavily 
influenced by extreme probe expression levels [19]. 
 
Model  
One general exon expression model was developed to describe the association between and exon 
expression and GBM survival adjusted for other clinical factors. Three specifications of the 
model accommodated three groups of genes: 1) multi-exon genes exhibiting AEU, 2) multi-exon 
genes with no evidence of AEU, and 3) single-exon genes.   The general model is: 
yijklmn = µ+ Gi + Rj + Tk + Sl + Em + (SE)lm + Pn + eijklmn [1] 
where yijklmn denotes the expression of the mth exon (Em), recorded on the nth patient (Pn) that 
has the ith gender (Gi), jth race\ethnicity (Rj), received the kth therapy (Tk), and survived lth 
months after diagnostic (Sl). In addition, eijklmn is the residual associated with the yijklmn 
observation and SE denotes the interaction between survival and exon on expression levels. 
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Fixed effects are G, R, T, and S. Random effects E, SE, and P are assumed each to be 
independent and follow a Gaussian distribution with its own variance. 
Model [1] allows the study of two scenarios (groups 1 and 2). First, a significant SE effect 
constitutes evidence of an AEU scenario and thus differential survival across exons. This model 
can be used to identify AS biomarkers of GBM survival that exhibit AEU. Second, a significant 
S effect together with a non-significant SE effect constitutes evidence of a general association 
between gene expression and survival, regardless of exon. In addition, a significant E effect 
indicates that the exons have differential expression. However, the association between the exons 
expression and survival is similar because SE is non-significant. This result can be used to 
identify multi-exon biomarkers of GBM survival that do not exhibit AEU.  
The specification for the single-exon gene (group 3) is a reduced version of the full multi-exon 
model [1] that excludes E and SE. Like with the multi-exon model under non-significant SE, a 
significant S effect is evidence of association between the single-exon gene expression and 
survival and can be used to identify single-exon biomarkers of GBM survival. 
The novel gene-centered analysis allows accounting for the covariance between exon expression 
within a gene and the hierarchical nature of the model allows the inclusion of the covariance 
between exon expression within a patient. The analysis of expression data at the exon level 
permitted the identification of AEU by testing the null hypothesis of no differential association 
between expression and survival across exons within a gene.  
False Discovery Rate adjustment (FDR) of the P-values allowed controlling for multiple testing 
(Benjamini and Hochberg) [20]. In addition, a more stringent P-value threshold was considered 
for the detection of AEU associations with survival (significant SE) relative to the detection of a 
general association between gene expression and survival (significant S) in the multi-exon 
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scenarios. The more stringent P-values required for detection of AEU accounted for the multiple 
comparisons of the survival-expression associations among potentially numerous exons. A 
separate FDR adjustment of the P-values from the single-exon analysis was implemented 
because of the different number of parameters between the multi- and single-exon models. The 
P-value < 5.0E-4 corresponds to a FDR adjusted P-value < 5.0E-2or multi exon genes and to a 
FDR adjusted P-value < 1.0E-1for genes with single exon. 
Functional and pathway analyses of the genes exhibiting significant evidence (P-value < 5.0E-4) 
of AEU associated with GBM survival used hypergeometric tests and was implemented in 
DAVID (http://david.abcc.ncifcrf.gov/) [21, 22]. Gene set enrichment analysis of the association 
between expression and GBM survival among all the genes studied in the platform followed the 
approach described by Subramanian et al. [23] implemented in BABELOMICS 4.3 
(http://babelomics.bioinfo.cipf.es/index.html, [24]. For this analysis, the association between 
each gene and survival was characterized by the estimate of change in expression per additional 
survival month standardized by the standard error of the estimate. The enrichment of Gene 
Ontology (GO; http://www.geneontology.org/) biological processes, molecular functions, and 
KEGG (http://www.genome.jp/kegg/pathway.html) pathways was investigated. Finally, P-values 
of the enriched categories were adjusted for multiple testing using the FDR correction. 
We recognize that statistical evidence is one component in the identification of AEU. However, 
it is biologically unlikely that AS events skip single or two exons across a gene. In addition, 
changes in the association between exon expression and survival may be statistically significant 
due to the substantial number of patients studied but may only represent small fold changes.  
Thus, three types of evidence were used to identify AEU.  We looked for a) significant variations 
in the associations between exon expression and survival across a gene, b) consistent (over or 
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under-expressed) differential expression in multiple consecutive exons, and c) a minimum exon 
differential expression (< 0.995 or > 1.005 fold change / additional survival month).  Consistent 
patterns of expression across consecutive exons were identified using a moving average analysis 
[25]. A moving average analysis that computes the average expression across multiple exons at a 
time was used to predict a continuous trajectory of exon expression across the gene. This moving 
average trend of exon expression across the gene facilitated the identification of consistent 
changes in the pattern of over or under-expression across the exons within a gene.  
The exon expression estimates and the moving average trajectory of the estimates across 
individual genes were aligned to known or predicted alternative transcript variants reported in 
the AceView database 
(http://genome.ucsc.edu/cgibin/hgTrackUi?hgsid=243882995&g=acembly&hgTracksConfigPag
e=configure) that are available through the UCSC Genome Browser (http://genome.ucsc.edu). 
This visualization strategy facilitated the interpretation of results and the AS models offered an 
independent in silico confirmation of the AEU events identified. 
 
Validation Dataset 
Genes exhibiting AEU in the training data set were confirmed in an independent set of 78 
patients obtained from the same repository. The reliability of the exon expression profiles 
associated with survival identified in the training data set was assessed using a two-stage 
approach. First, the parameter estimates (i.e. changes in exon expression per one month increase 
in survival) obtained from the analysis of the training data set were applied to the covariate 
information from the patients in the validation data set and predictions of exon expression were 
obtained. Second, the predicted exon expression values were compared to the corresponding 
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observed expression values. The performance of the training estimates was evaluated using the 
coefficient of determination (R
2
) indicators [26].  High R
2
 on the validation data set based on the 
training data set estimates indicate the reliability of the exon expression patterns identified. 
 
Results and Discussion 
Expression measurements of 269951 exons from 25403 genes were analyzed. Of these, 2857, 
20288, 1965 and 293 genes had one, 2 to 24, 25 to 49 and 50 or more exons, respectively. The 
number of exons per gene ranged from 1 to 191 and the average number of exons was 10.75. 
Table 1 summarizes the distribution of the 250 and 78 individuals diagnosed with GBM analyzed 
in the training and validation data sets respectively, across clinical factors and survival 
descriptive statistics. The distribution of observations across clinical factors was consistent 
across data sets. 
The results from training data set are summarized in three groups according to the model used 
and evidence supporting AEU: 1) multi-exon genes exhibiting exon dependent association with 
GBM survival or AEU (group 1 genes), 2) multi-exon genes exhibiting exon-independent 
association with GBM survival or no AEU (group 2 genes), and 3) single-exon genes exhibiting 
association with GBM survival (group 3 genes). The general model proposed supports the 
consistent analysis of single-exon and multi-exon genes and identifies gene or exon associations 
with survival. The general and hierarchical nature of the model permits testing a myriad of 
hypothesis. The consideration of an interaction between survival and exon allowed the 
identification of associations between particular exons and survival and corresponding 
characterization of AEU (exon-specific fold change /additional survival month).  
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Table 1. Distribution of patients with glioblastoma multiforme analyzed by level of clinical 
factors. 
 
  Training data set  Validation data set 
  Number Percentage  Number  Percentage 
Patients   250  76.22   78 23.78 
Race
1
  
Caucasian 222 88.80  71 91.03 
Other 28 11.20  07 8.97 
Gender 
Females 94 37.60  29 37.18 
Males 156 62.40  49 62.82 
Therapy
2
 
R 63 25.20  21 26.92 
CRT 27 10.80  07 8.97 
CRnT 99 39.60  31 39.74 
OTHER 35 14.00  10 12.82 
NONE 26 10.40  09 11.54 
Survival 
(months) 
 17.46 0.16 - 128  15.02 0.10 – 77.57 
 
1
Race: White Caucasian, and all other race-ethnicity groups 
2
Therapy; R: radiation therapy alone; CRnT: chemotherapy plus radiation and no targeted therapy; CRT: 
chemotherapy plus radiation and targeted therapy; OTHER: all other therapies
 
None: no therapy. 
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In the event of non-significant exon-by-survival interaction, the inclusion of a general survival 
covariate allowed the detection of a general association between gene expression and survival 
that does not differ among exons. The novel modeling of exons as random effect levels permitted 
the specification of a variance-covariance structure between the exons within a gene. The 
removal of exon-dependent terms from the full multi-exon model offered a model suitable for 
single-exon genes.  In addition, the block patient effect accommodates the covariance between 
exon levels measured in the same patients. 
 
Multi-Exon Genes Exhibiting Exon-Dependent Association with Glioblastoma Multiforme 
Survival 
At unadjusted P-value < 5.0E-4 (equivalent to FDR-adjusted P-value < 5.0E-2), 2477 multi-exon 
genes exhibited AEU associated with survival (group 1 genes), 24 multi-exon genes exhibited 
expression associated with survival albeit no evidence of AEU (group 2 genes), and 8 single-
exon genes exhibited expression associated with survival (group 3 genes). At P-value < 1.0E-5, 
P-value < 1.0E-6, P-value < 1.0E-7, P-value < 1.0E-8, the number of genes exhibiting AEU 
(group 1 genes) were 592, 313, 201, and 129 respectively. 
Table 2 summarizes the top 36 multi-exon genes that have the most significant (P-value < 1.0E-
11) AEU or exon-dependent association with GBM survival (group 1 genes) due to space 
constraints. 
The nature of the association between expression and GBM is characterized by the sign and 
value of the expression fold change per additional month in survival. Tables 2, 4, and 5 include a 
general gene-wise estimate of expression fold change per additional month in survival for multi-
exon with (group 1) and without AEU (group 2) and single-exon (group 3) genes. The meaning 
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of this fold change estimate is straightforward for group 2 and 3 genes because these genes 
exhibit a single general association with GBM survival, Attention should be exercised when 
interpreting the general fold change estimate for group 1 AEU genes because these genes exhibit 
significant variation in association between expression and survival among exons.  
The top 36 genes exhibiting significant evidence of AEU have a minimum of 90 exons (Table 2). 
This result suggests that genes with high number of exons are more likely to experience AEU 
events that influence GBM survival. It is unlikely that high number of exons biased the 
identification of AEU because a stringent P-value threshold was used. 
Among the 36 genes that have significant AEU association with GBM survival most have been 
related to cancer.  Of these, 10 genes including titin (Ttn), polycystic kidney disease 1 (Pkd1), 
spectrin repeat containing, nuclear envelope 1 (Syne1), small nuclear ribinucleoprotein (Snrpn), 
phosphodiesterase 4D interacting protein (Pde4dip), obscurin (Obscn), dystonin (Dst), 
microtubule-actin cross-linking factor 1 (Macf1), ryanodine receptor 1 (Ryr1) and ryanodine 
receptor 2 (Ryr2) have been previously associated with GBM. Additionally, 13 genes Smg-1 
homolog (Smg1), Nebulin (Neb), TBC1 domain family, member 3 (Tbc1d3), Anaphase 
promoting complex subunit 1 (Anapc1), Spectrin repeat containing, nuclear envelope 1 (Syne2), 
Neuroblastoma breakpoint family, member 10 (Nbpf10), Mucin 19 (Muc19), Collagen, type VII, 
alpha 1 (Col7a1), Ubiquitin protein ligase E3 component n-recognin 4 (Ubr4), Hemicentin 1 
(Hmcn1), Collagen, type IV, alpha 5 (Col4a5), Ryanodine receptor 3 (Ryr3), G protein-coupled 
receptor 98 (Gpr98) have been previously associated to cancers other than GBM. The list of 
references is summarized in Table 2. Additionally, literature review also supported the presence 
of AS in most of the genes. 
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Table 2. Top 36 multi-exon genes that have significant alternative exon usage associated 
with glioblastoma multiforme survival.  
 
Gene 
Symbol 
Estimate
1
 SE
2
 P-value 
AEU
3
 
Fold 
change
4
 
Exon 
Count
5
 
Literature
6
 
Ttn 0.0007 0.0001 4.2E-38 0.9993 340 [27] 
G 
Smg1 0.0017 0.0002 2.0E-24 1.0001 209 [70] 
AS
 
Neb 0.0007 0.0001 3.2E-21 0.9973 180 [71, 72]
C, AS
 
Pkd1 0.0010 0.0001 2.0E-19 1.0018 163 [28] 
G, AS
 
Herc2p2 0.0008 0.0001 2.3E-19 1.0012 163 NA 
Syne1 0.0018 0.0002 3.0E-18 0.9984 152 [9] 
G
 
Snrpn 0.0018 0.0002 3.8E-18 1.0020 151 [29, 73]
G, AS
 
Pde4dip 0.0016 0.0002 1.3E-17 0.9993 146 [30, 74]
G, AS
 
Golga8c 0.0031 0.0004 4.2E-17 1.0005 141 NA 
Sspo 0.0009 0.0001 1.2E-16 1.0003 137 NA 
Ankrd36 0.0026 0.0003 1.3E-16 1.0018 137 NA 
Tbc1d3 0.0008 0.0001 2.4E-16 1.0026 135 [75]
C
 
Flj45340 0.0018 0.0002 5.5E-16 1.0007 131 NA 
Anapc1 0.0009 0.0001 5.8E-15 0.9990 122 [59, 76]
C, AS
 
Syne2 0.0012 0.0002 6.2E-15 1.0017 115 [77]
C, AS
 
Nbpf10 0.0035 0.0005 1.3E-14 0.9992 118 [78]
 C, AS
 
Muc19 0.0015 0.0002 1.4E-14 1.0001 118 [79]
C, AS
 
Obscn 0.0006 0.0001 1.5E-14 0.9999 118 [27, 80]
G, AS
 
Npipl3 0.0019 0.0003 4.1E-14 1.0014 114 NA 
Dst 0.0013 0.0002 9.4E-14 0.9997 111 [31, 81]
G, AS
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Table 2 (Contd) 
Col7a1 0.0011 0.0001 1.4E-13 1.0001 109 [82, 83]
C, AS
 
Ubr4 0.0011 0.0001 1.4E-13 0.9994 109 [84, 85]
C, AS
 
Hmcn1 0.0006 0.0001 2.0E-13 0.9975 109 [86]
C, AS
 
Ryr2 0.0011 0.0001 2.7E-13 0.9974 107 [34, 87]
G, AS
 
Macf1 0.0011 0.0002 3.1E-13 0.9975 106 [32, 88]
G, AS
 
Mdn1 0.0006 0.0001 3.5E-13 0.9993 106 NA 
Col4a5 0.0008 0.0001 3.5E-13 0.9992 106 [89, 90]
C, AS
 
Ryr1 0.0007 0.0001 4.2E-13 0.9998 105 [33, 72, 91]
G, AS
 
Golga6l5 0.0013 0.0002 5.2E-13 1.0021 104 NA 
Ryr3 0.0009 0.0001 1.3E-12 0.9962 102 [92]
C, AS
 
Dnah14 0.0007 0.0001 2.0E-12 0.9990 99 NA 
Herc2 0.0006 0.0001 3.1E-12 1.0003 97 [60]
AS
 
Dnah8 0.0005 0.0001 4.7E-12 0.9997 96 NA 
Nomo1 0.0007 0.0001 4.9E-12 0.9996 95 NA 
Gpr98 0.0016 0.0002 5.9E-12 0.9948 95 [67]
C, AS
 
Golga6a 0.0017 0.0002 7.8E-12 1.0009 93 NA 
 
1
Estimate: exon-survival interaction variance indicator of alternative exon usage; 
2
SE: standard error of the estimate; 
3
P-value AEU: unadjusted P-value of alternative exon usage or exon-dependent association between 
expression and glioblastoma multiforme survival. 
4
Fold change: fold change in average exon expression per additional survival month; 
5
Exon Count: number of exons in the gene;  
6
Literature: review of studies that reported associations of the gene with cancers: 
G
: reported association of gene with glioblastoma multiforme; 
C
: reported association of gene with cancer other than glioblastoma multiforme. 
AS
: identification of different variants due to alternative splicing (AS) event. 
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Ttn encodes the protein TTN that is responsible for the passive elasticity of cells. A mutation 
resulting in an altered TTN was associated with GBM [27]. Pkd1 was over-expressed during the 
progression of low-grade to high-grade gliomas [28]. Syne1 has been associated with increased 
GBM survival [9].  Under- expression of Snrnp was observed in older GBM patients [29]. 
Pde4dip is down-regulated in glioma cell lines treated with dB-cAMP that reduces the 
invasiveness, proliferation and migratory properties of glioma cells and increases the survival of 
glioma cells lines [30]. The mutation R4558H in Obscn has been associated with GBM [27]. 
Likewise, a mutation in Dst that indirectly regulates the expression of Otub1 (through regulation 
of mir-15b has been associated with GBM [31]. Reduced expression of Macf1 has been observed 
in glioma cells treated with IL-13 cytotoxin that causes the cells to undergo necrosis. Thus, 
down-regulation of the expression of Macf1 is associated with increased GBM survival [32]. 
Ryr1 was under-expressed in high-grade gliomas relative to primary (low-grade) gliomas [33]. 
On the other hand Ryr2 was over-expressed in invasive GBM cells [34]. 
 
Functional and Pathway Analyses of the Multi-Exon Genes Exhibiting Exon-Independent 
Association with Glioblastoma Multiforme Survival 
The list of 2477 genes exhibiting significant evidence of AEU associated with GBM survival 
was further investigated using functional and pathway analyses. At FDR adjusted P-value < 
5.0E-2, 15 KEGG pathways, 87 GO biological processes, and 70 GO molecular functions were 
enriched. The top 10 pathways, biological processes and molecular functions are summarized in 
Table 3. Among the 15 KEGG pathways significantly enriched, focal adhesion was the most 
significant pathway encompassing 86 genes. This result is consistent with many reports of the 
critical role of focal adhesion and gliomas [35-37]. The extra-cellular matrix- (ECM-) receptor 
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interaction pathway enrichment detected in this study has been reported in other cancers [38, 39]. 
The ATP-binding cassette (ABC) transporter pathway has been associated with gliomas [40]. 
Our finding of small cell lung carcinoma pathways enrichment associated with GBM is 
consistent with the multiple studies that have identified commonalities among these cancers [41]. 
The most enriched biological process among the AEU genes associated with GBM survival 
included regulation of small GTPase mediated signal transduction (RSGST), and neuron 
development that has been associated with neuroblastoma [42]. The enrichment of biological 
adhesion confirms our focal adhesion results. Among the top 70 GO molecular functions 
significantly enriched were: adenyl nucleotide binding, adenyl ribonucleotide binding, ATP 
binding, nucleotide binding and helicase activity. These related nucleotide binding functions 
have been associated with GBM [43]. 
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Table 3. Ten most significant KEGG and GO categories enriched among the genes 
displaying alternative exon usage. 
Source Category 
Gene 
Count
1
 
FDR 
P-value
2
 
KEGG  
Pathway 
(hsa04510) focal adhesion 86 3.2E-21 
(hsa04512) ecm-receptor interaction  51 8.5E-20 
(hsa02010) abc transporters  30 2.5E-12 
(hsa04810) regulation of actin cytoskeleton  66 1.7E-07 
(hsa05412) arrhythmogenic right ventricular 
cardiomyopathy  
32 5.9E-06 
(hsa05414) dilated cardiomyopathy  37 1.3E-06 
(hsa04070) phosphatidylinositol signaling system  31 1.2E-05 
(hsa05222) small cell lung cancer  31 3.6E-04 
(hsa05410) hypertrophic cardiomyopathy  32 1.3E-04 
(hsa05200) pathways in cancer  73 3.0E-02 
GO 
Biological 
Process 
(GO:0051056) regulation of small GTPase 
mediated signal transduction  
105 5.0E-25 
(GO:0022610) biological adhesion  197 2.7E-22 
(GO:0007155) cell adhesion  197 2.3E-22 
(GO:0046578) regulation of Ras protein signal 
transduction  
79 5.0E-15 
71 
 
Table 3 (Contd) 
 
(GO:0035023) regulation of Rho protein signal 
transduction  
51 1.7E-15 
 (GO:0007010) cytoskeleton organization  129 1.3E-15 
 (GO:0030029) actin filament-based process  85 2.3E-14 
 (GO:0007018) microtubule-based movement  51 2.1E-12 
 (GO:0016568) chromatin modification  89 1.9E-12 
 (GO:0051276) chromosome organization  132 1.4E-12 
GO 
Molecular 
Function 
(GO:0030554) adenyl nucleotide binding  451 9.9E-59 
(GO:0005524) ATP binding  433 2.2E-59 
(GO:0032559) adenyl ribonucleotide binding  437 2.0E-59 
(GO:0001882) nucleoside binding  456 6.3E-58 
(GO:0001883) purine nucleoside binding  451 1.5E-56 
(GO:0017076) purine nucleotide binding  480 5.2E-44 
(GO:0032555) purine ribonucleotide binding  466 2.9E-44 
(GO:0032553) ribonucleotide binding  466 2.9E-44 
(GO:0000166) nucleotide binding  523 7.4E-39 
(GO:0003774) motor activity  86 1.3E-34 
1
Gene Count: number of genes that have significant alternative exon usage within category. 
2
FDR P-value: False discovery rate adjusted P-value of the hyper-geometric test of category enrichment. 
72 
 
Multi-Exon Genes Exhibiting Exon-Independent Association with Glioblastoma Multiforme 
Survival 
At unadjusted P-value < 5.0E-4 (equivalent to FDR-adjusted P-value < 5.0E-2), 24 multi-exon 
genes exhibited exon-independent association with GBM survival (group 2 genes). In other 
words, there was no evidence of AEU in these genes because the expressions of all the exons 
were consistently associated with GBM survival and a single general or overall association 
between the gene and survival can be identified. Table 4 lists the top five multi-exon genes that 
have the most significant exon-independent association with GBM survival. 
Among the 24 multi-exon genes that were associated with GBM survival on a general, exon-
independent manner, the five genes that have the lower AEU evidence (AEU unadjusted P-value 
> 1.0E-3, approximately FDR adjusted P-value > 1.0E-1) are listed in Table 4. The expression of 
three of these genes increased with increasing survival. Noteworthy was the low number of 
exons in these genes, relative to the higher number of exons in genes exhibiting evidence of 
AEU. 
Four of five multi-exon genes have been associated to different cancers in studies listed in Table 
4 and the remaining gene is uncharacterized (LOC100289627). Sirtuin2 (Sirt2) has been 
associated with GBM while the other three genes golgin subfamily A member 8J (Golga8j), 
semaphorin 3E (Sema3e) and SIX homeobox 1 (SIX1) were associated with other cancers. 
Under-expression of Sirt2 has been reported in glioma cells [44]. This result is also consistent 
with our findings that higher levels of Sirt2 were associated with higher GBM hazard. Golga8j 
has been associated with pancreatic cancer and the trend is consistent with our finding of lower 
GBM survival with higher expression levels of this gene [45].   
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Table 4. Top 5 multi-exon genes that have significant exon-independent  association with 
glioblastoma multiforme survival.  
 
Gene 
Symbol 
Estimate
1
 SE
2
 
Fold 
Change
3
 
P-value
4
 
P-val  
AEU
5
 
Exon 
Count
6
 
Litera
ture
7
 
Sirt2 0.0337 0.0092 1.0236 3.2E-04 2.5E-03 17 [44]
G
 
Six1 0.0056 0.0015 1.0039 3.3E-04 2.7E-01 05 [48]
C
 
Loc 
100289627 
0.0079 0.0022 1.0055 3.8E-04 4.3E-01 02 NA 
Sema3e -0.0256 0.0066 0.9824 1.3E-04 2.4E-03 18 [46]
C
 
Golga8j -0.0536 0.0141 0.9635 1.7E-04 1.1E-03 20 [45]
C
 
 
1
Estimate: change in average exon expression per additional survival month (in log2 units); 
2
SE: standard error of the estimate; 
3
Fold change: fold change in average exon expression per additional survival month; 
4
P-value: unadjusted P-value of the change in average exon expression per additional survival month; 
5
P-value AEU: non-significant (P-value > 1.0E-03) evidence of alternative exon usage; 
6
Exon Count: number of exons in the gene; 
7
Literature: review of studies that reported associations of the gene with cancers; 
G
: reported association of gene with glioblastoma multiforme; 
C
: reported association of gene with cancer other than glioblastoma multiforme. 
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Sema3e promotes invasiveness and metastatic ability of the cancerous cells [46]. Sema3e is 
associated with many cancers like prostate cancer colon cancer and lung adenocarcinoma [47]. 
This result is consistent with our findings that higher levels of Sema3e were associated with 
lower GBM survival. The gene Six1 is associated with lower survival in cancerous cells [48]. 
This result is inconsistent with our results showing an increase in Six1 expression associated with 
an increase in GBM survival. 
 
Single-Exon Genes Associated with Glioblastoma Multiforme Survival 
Eight single-exon genes were associated with GBM survival (group 3 genes) at unadjusted P-
value < 5.0E-4 (equivalent to FDR-adjusted P-value < 5.0E-2. Table 5 summarizes the results 
corresponding to these 8 single-exon genes. Among these, three genes had a negative 
relationship such that lower expression levels were associated with higher survival (Table 5). 
Four members of the family of small nucleolar RNA CD box (Snord) genes were associated with 
GBM survival and three had a positive association such that higher expression levels were 
associated with higher survival. These results are consistent with previous work. Snord are a type 
of small nucleolar RNA (SnoRNA) that guide the methylation of rRNAs and snRNAs. These 
snoRNAs can target other RNAs and are associated with carcinogenesis. Their reduced and 
dysregulated expression has been associated with progression of many human malignancies [49]. 
Along with their loss in brain tumorigenesis, snoRNA have also been linked to other cancers 
such as prostate, breast and lung cancer [49, 50]. In this study, a positive association between the 
levels of H1 histone family member 0 (H1f0) and GBM survival was identified. The expression 
of H1f0 was high in breast tumor cells, and decreased when the breast tumor cell lines were 
reverted back into normal ME cells [51]. 
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Table 5: Results corresponding to 08 single-exon genes associated with glioblastoma 
multiforme survival (group 3 genes).  
 
Gene symbol Estimate
1
 SE
2
 
Fold 
Change
3
 
P-value
4
 Literature
5
 
Hist1h1t 0.0118 0.0024 1.0082 2.5E-06 NA 
Snord116-11 0.0101 0.0025 1.0070 9.7E-05 [50]
C
 
Loc729852 -0.0074 0.0018 0.9949 5.8E-05 NA 
Snord123 -0.0087 0.0025 0.9940 4.8E-04 [50]
C
 
Snord104 0.0067 0.0019 1.0047 4.1E-04 [50]
C
 
Dkfzp779l1853 -0.0083 0.0023 0.9943 3.9E-04 NA 
H1f0 0.0062 0.0017 1.0043 2.3E-04 [51]
C
 
Snord28 0.0166 0.0044 1.0116 1.8E-04 [50]
C
 
 
The table includes group 3 single-exon genes that are associated with glioblastoma multiforme survival.
  
1
Estimate: change in gene expression per additional survival month (in log2 units); 
2
SE: standard error of the estimate; 
3
Fold change: fold change in gene expression per additional survival month; 
4
P-value: unadjusted P-value of the change in average exon expression per additional survival month; 
5
Literature:  review of studies that reported associations of the gene with cancers;
C
: associated with cancer 
other than glioblastoma multiforme. 
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Gene Set Enrichment Analyses of All Genes in Consideration of their Association with 
Glioblastoma Multiforme Survival 
Gene set enrichment analysis considered the level and sign of association between the expression 
of all the genes studied and GBM survival. At FDR adjusted P-value < 5.0E-2, 94 KEGG 
pathways, 402 GO biological processes, and 203 GO molecular functions were enriched. Results 
from the top 10 most significant pathways, biological processes and molecular functions are 
summarized in Tables 6, 7 and 8. Pathways and GO categories are characterized in GSEA by the 
number of genes that have a positive or negative association between expression and GBM 
survival, by the log odds ratio indicating whether the category is more enriched among the genes 
that have a positive or negative association and the corresponding P-value. Positive (or negative) 
loge odds ratio indicates that the enrichment was higher among the genes with positive (or 
negative) association with GBM survival. Extreme values indicate higher difference in the 
enrichment percentages between the positive and negative association groups, meanwhile values 
close to zero indicate similar enrichment percentages between positive and negative association 
groups. 
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Table 6. Ten most significant GO biological processes from the gene set enrichment 
analysis of the genome. 
GO 
Identifier 
GO Biological 
Process 
Over 
Expressed 
Gene
1
 
Under 
Expressed 
Genes
2
 
Log Odds 
Ratio
3
 
FDR       
P-value
4
 
GO:0046907 
intracellular 
transport 
357 560 -0.7338 3.79E-24 
GO:0034613 
cellular protein 
localization 
245 433 -0.8490 4.78E-24 
GO:0043067 
regulation of 
programmed 
cell death  
351 490 -0.6110 1.68E-15 
GO:0016192 
vesicle-
mediated 
transport 
271 400 -0.6639 1.16E-14 
GO:0006629 
lipid metabolic 
process 
424 538 -0.5148 1.30E-12 
GO:0044265 
cellular 
macromolecule 
catabolic 
process  
373 485 -0.5379 2.10E-12 
GO:0044255 
cellular lipid 
metabolic 
process  
346 457 -0.5528 2.41E-12 
GO:0050793 
regulation of 
developmental 
process  
442 549 -0.4932 4.27E-12 
GO:0007049 cell cycle  418 522 -0.4978 1.11E-11 
GO:0009966 
regulation of 
signal 
transduction  
414 509 -0.4812 9.93E-11 
 
1
Over Expressed Genes: number of genes that have a positive association between expression and 
glioblastoma multiforme survival; 
2
Under Expressed Genes: number of genes that have a negative association between expression and 
glioblastoma multiforme survival; 
3
Log Odds Ratio: indicates whether the category is more enriched among the genes that have a positive 
association between expression and survival relative to the enrichment among the genes that have a negative 
association between expression and glioblastoma survival (positive loge odds ratio) or vice versa (negative loge 
odds ratio). Extreme values indicate higher difference in the enrichment percentages between the positive and 
negative association groups meanwhile values close to zero indicate similar enrichment percentages between 
positive and negative association groups; 
4
FDR P-value: False discovery rate adjusted P-value of the log odds ratio test. 
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Table 7. Ten most significant GO molecular functions from the gene set enrichment 
analysis of the genome. 
GO 
Identifier 
GO Molecular 
Function 
Over 
Expressed 
Gene
1
 
Under 
Expressed 
Genes
2
 
Log 
Odds 
Ratio
3
 
FDR       
P-value
4
 
GO:0000287 
magnesium ion 
binding  
196 300 -0.6962 3.23E-11 
GO:0016818 
hydrolase activity, 
acting on acid 
anhydrides, in 
phosphorus 
containing 
anhydrides 
419 521 -0.4933 5.21E-11 
GO:0016462 
pyrophosphatase 
activity 
417 520 -0.4962 5.21E-11 
GO:0016817 
hydrolase activity, 
acting on acid 
anhydrides  
428 527 -0.4834 9.62E-11 
GO:0016773 
phosphotransferase 
activity, alcohol 
group as acceptor  
393 475 -0.4624 5.64E-09 
GO:0016301 kinase activity 421 501 -0.4473 5.64E-09 
GO:0016788 
hydrolase activity, 
acting on ester 
bonds 
349 429 -0.4781 9.84E-09 
GO:0003723 RNA binding  357 437 -0.4741 9.84E-09 
GO:0030695 
GTPase regulator 
activity 
193 260 -0.5651 4.10E-07 
GO:0016874 ligase activity 205 272 -0.5501 4.10E-07 
1
Over Expressed Genes: number of genes that have a positive association between 
expression and glioblastoma multiforme survival; 
2
Under Expressed Genes: number of genes that have a negative association between 
expression and glioblastoma multiforme survival; 
3
Log Odds Ratio: indicates whether the category is more enriched among the genes that 
have a positive association between expression and survival relative to the enrichment 
among the genes that have a negative association between expression and glioblastoma 
survival (positive loge odds ratio) or vice versa (negative loge odds ratio). Extreme values 
indicate higher difference in the enrichment percentages between the positive and negative 
association groups meanwhile values close to zero indicate similar enrichment percentages 
between positive and negative association groups; 
4
FDR P-value: False discovery rate adjusted P-value of the log odds ratio test. 
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Table 8. Ten most significant KEGG pathways from the gene set enrichment analysis of the 
genome. 
KEGG 
Identifier 
KEGG Pathway 
Over 
Expressed 
Gene
1
 
Under 
Expressed 
Genes
2
 
Log 
Odds 
Ratio
3
 
FDR       
P-value
4
 
hsa03010 ribosome 119 16 -2.4779 9.7E-10 
hsa00010 
glycolysis / 
gluconeogenesis 
57 27 -1.1614 3.6E-04 
hsa00190 
oxidative 
phosphorylation  
103 39 -0.9392 3.6E-04 
hsa05212 pancreatic cancer  54 45 -0.9460 4.7E-04 
hsa05130 
pathogenic 
escherichia coli 
infection  
44 41 -1.0575 4.7E-04 
hsa00240 
pyrimidine 
metabolism  
42 78 -0.8800 5.0E-04 
hsa03050 proteasome  33 32 -1.0965 7.2E-04 
hsa00280 
valine, leucine and 
isoleucine 
degradation  
20 48 -1.1353 8.5E-04 
hsa04662 
b cell receptor 
signaling pathway  
34 65 -0.9084 8.5E-04 
hsa05223 
non-small cell 
lung cancer  
25 52 -0.9922 9.0E-04 
 
1
Over Expressed Genes: number of genes that have a positive association between expression and 
glioblastoma multiforme survival; 
2
Under Expressed Genes: number of genes that have a negative association between expression and 
glioblastoma multiforme survival; 
3
Log Odds Ratio: indicates whether the category is more enriched among the genes that have a positive 
association between expression and survival relative to the enrichment among the genes that have a negative 
association between expression and glioblastoma survival (positive loge odds ratio) or vice versa (negative loge 
odds ratio). Extreme values indicate higher difference in the enrichment percentages between the positive and 
negative association groups meanwhile values close to zero indicate similar enrichment percentages between 
positive and negative association groups; 
4
FDR P-value: False discovery rate adjusted P-value of the log odds ratio test. 
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Noteworthy was that all top ten results had negative log odds ratio indicating that the categories 
were more enriched among the genes that have a negative association between expression and 
survival relative to the enrichment among the genes that have a positive association between 
expression and GBM survival. Positive log odds ratios were observed for less significant (P-
value < 5.0E-2) pathways and categories. The more extreme log odds ratios observed in the 
GSEA of KEGG pathways indicate higher difference between the enrichment percentages in the 
positive and negative association groups meanwhile values close to zero in the GSEA of GO 
categories indicate lower differences in the enrichment percentages between positive and 
negative association groups. 
Among the most differentially enriched pathways (Table 6) were cancer pathways (pancreatic, 
non-small cell lung). Additional pathways identified in this study that have been associated with 
gliomas include glycolysis/gluconeogenesis [52] and oxidative phosphorylation [53]. Among the 
top enriched GO biological processes, lipid metabolism and cell cycle have been associated with 
glioma [54, 55]. Likewise, several GO molecular functions hydrolase and ligase activities have 
been have been linked to glioma [56, 57].  
 
Demonstration of Alternative Exon Usage 
The identification of patterns of differential exon expression across a gene and comparison 
against predicted AS models helped to confirm associations between AS and survival. Figures 
2.1 to 2.4 depict patterns of exon expression associated with GBM survival and reported AS 
gene models for three genes among the 36 genes that exhibited the highest significant AEU 
associated with GBM survival (Table 2) and one gene of biological relevance that have AEU at 
P-value < 5.0E-4. The four genes depicted in Figures 2.1 to 2.4 are anaphase promoting complex 
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subunit 1 (Anapc1, Figure 2.1), HECT domain and RLD domain containing E3 ubiquitin protein 
ligase 2 (Herc2, Figure 2.2), G-protein coupled receptor 98 (Gpr98, Figure 2.3), and epidermal 
growth factor (Egf, Figure 2.4).The parallel alignment of estimated exon expression resulting 
from our analysis, the moving average trend and the AS prediction from AceView offered in 
silico verification of the identified AEU [3]. The AS models are denoted by lines parallel to the 
x-axis and identify the corresponding exons. However, no expression values should be assigned 
to the AS model lines and experimental confirmation of the AEU cases identified in this study is 
necessary. 
Anapc1 is located on human chromosome (HAS) 2 and the function of this gene is associated 
with transition in the cell cycle from metaphase to anaphase [58]. In agreement with the function, 
premature truncation of the gene leading to reduced expression of Anapc1 is associated with 
cancer development [59]. Six AS models for this gene were found in the alternative transcript 
variant database ACE View. Anapc1exhibited AEU in this study and of the 48 exons analyzed, 
the expression of 25 exons was associated with GBM survival (Figure 2.1). The AS pattern 
predicted by our model and highlighted by the moving average trend is supported by AS gene 
models (Anapc1.d, and Anapc1.e, Figure 2.1). Our model predicted under-expression of the 
majority of the exons in three gene models (Anapc1.d, Anapc1.e and Anapc1.g). The under 
expression of exons associated with higher survival predicted by our model and presented in 
Figure 2.1 are in consistent with previous studies of the relationship between Anapc1 and cancer 
[59]. Consistent with the functional analysis, Anapc1 pertains to enriched GO biological process 
of cell cycle phase and axonogenesis and the KEGG pathway Ubiquitin mediated proteolysis.  
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Herc2 is located on HAS 15 and belongs to the ubiquitin ligase family HERC. Various members 
of this family have high expression in fetal relative to adult brain [60]. Herc2 in mouse has been 
associated with neuromuscular disorder, was and has been proposed to be related to neuronal 
tissues in humans. Also, mutations resulting in under expression of Herc2 have been related to 
gastric and colorectal carcinomas [61]. Significant AEU and association between GBM survival 
and expression were detected on 42 of the 93 exons in Herc2 (Figure 2.2). Our model predicted 
exon under-expression that overlap with several AS models (e.g. Herc.q, Herc.g, Herc.j, Herc.t). 
These trends are consistent with demonstrations that HERC2 depletion restores the breast cancer 
suppressor BRCA1 [62] and that resulting HERC2 protein formation and cancer [61]. Supporting 
our GO analyses and enriched categories, Herc2 belongs to the GO molecular function 
categories GTPase regulator activity and ion binding, the GO biological process of intracellular 
transport and protein localization and the KEGG pathway Ubiquitin mediated proteolysis.  
Gpr98 is located on HAS 5 and is highly expressed in the central nervous system (CNS) [63]. 
This gene has been associated with Usher syndrome and Familial Febrile seizures. Usher 
syndrome is characterized by hearing loss and progressive vision loss, whereas the Febrile 
Convulsions is a form of seizure effecting children [64, 65]. Studies have r association of Gpr98 
with cancer [66] and also revealed that smaller variants of Gpr98, produced due to AS, are 
associated with increased survival against lymphoblastic leukemia [67]. Gpr98 exhibited AEU in 
this study and the expression of approximately 30 exons (out of 90 exons) exhibited significant 
association with GBM survival (Figure 2.3). Several over-expressed exons detected by our 
model are consistent with AS gene models including Mass1.b, Mass1.f, Mass1.e, and Mass1.c.  
Conversely, some under-expressed exons identified in our study are supported by gene models 
including Mass1d and Mass1g. These results are consistent with previous studies that indicated 
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association of smaller transcripts of Gpr98 with cancer survival by inducing apoptosis in 
cancerous cells [67]. In agreement with our GO analyses, Gpr98 is affiliated to the enriched GO 
biological processes of cell adhesion, neuron development and sensory perception of mechanical 
stimulus. Additionally, Gpr98 has the GO molecular function of cytoskeletal protein binding and 
ion binding. 
Egf is located on HAS 4 and over-expression of Egf has been associated with tumor progression 
and lower GBM survival [68]. Egf exhibited AEU and of the 24 exons analyzed, nine exons had 
significant associations with GBM survival. Several over-expressed exons detected in our 
analysis correspond to AS gene models including Egf.j and Egf.h. In accord with the pathway 
and functional analyses, Egf is part of many enriched KEGG pathways including focal adhesion, 
regulation of actin cytoskeleton, and cancer pathways. 
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Figure 2.1. Anapc1 exon expression, moving average, and alternative splicing models.  
 
Anapc1: anaphase promoting complex subunit 1.  
X-axis: location of exons in the gene (in bp). 
Y-axis (left): change in exon expression per additional survival month calculated from the hierarchical model of alternative exon usage. 
Full diamond markers: exon expression from the hierarchical model of alternative exon usage is denoted by (Exon expression). 
Y-axis (right): indicator of alternative splicing model. 
Black and gray lines that have x, triangle, square, circle, +, or no markers: AceView alternative splicing models. Lines denote the location of the exons included in 
the model. Alternative splicing models do not have inherent expression levels.  
Continuous line: moving average pattern of expression based on 10 exons. 
Standard Error: standard error of the exon expression estimate. 
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Figure 2.2. Herc2 exon expression, moving average, and alternative splicing models. 
 
 Herc2: HECT domain and RLD domain containing E3 ubiquitin protein ligase 2.  
X-axis: location of exons in the gene (in bp). 
Y-axis (left): change in exon expression per additional survival month calculated from the hierarchical model of alternative exon usage. 
Full diamond markers: exon expression from the hierarchical model of alternative exon usage is denoted by (Exon expression). 
Y-axis (right): indicator of alternative splicing model. 
Black and gray lines that have x, triangle, square, circle, +, or no markers: AceView alternative splicing models. Lines denote the location of the exons included in 
the model. Alternative splicing models do not have inherent expression levels.  
Continuous line: moving average pattern of expression based on 10 exons. 
Standard Error: standard error of the exon expression estimate. 
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Figure 2.3. Gpr98 exon expression, moving average, and alternative splicing models. 
 
Gpr98: G-protein coupled receptor 98.  
X-axis: location of exons in the gene (in bp). 
Y-axis (left): change in exon expression per additional survival month calculated from the hierarchical model of alternative exon usage. 
Full diamond markers: exon expression from the hierarchical model of alternative exon usage is denoted by (Exon expression). 
Y-axis (right): indicator of alternative splicing model. 
Black and gray lines that have x, triangle, square, circle, +, or no markers: AceView alternative splicing models. Lines denote the location of the exons included in 
the model. Alternative splicing models do not have inherent expression levels.  
Continuous line: moving average pattern of expression based on 10 exons. 
Standard Error: standard error of the exon expression estimate. 
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Figure 2.4. Egf exon expression, moving average, and alternative splicing models. 
 
 
Egf: epidermal growth factor.  
X-axis: location of exons in the gene (in bp). 
Y-axis (left): change in exon expression per additional survival month calculated from the hierarchical model of alternative exon usage. 
Full diamond markers: exon expression from the hierarchical model of alternative exon usage is denoted by (Exon expression). 
Y-axis (right): indicator of alternative splicing model. 
Black and gray lines that have x, triangle, square, circle, +, or no markers: AceView alternative splicing models. Lines denote the location of the exons included in 
the model. Alternative splicing models do not have inherent expression levels.  
Continuous line: moving average pattern of expression based on 10 exons. 
Standard Error: standard error of the exon expression estimate. 
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Validation 
The average and range of R
2
 values from the application of training data set estimates on the 
training and validation data set were 0.8 and 0.7, respectively. These results indicate that the 
AEU events and genes associated with GBM survival detected and characterized in the training 
data set were confirmed in the independent validation data set.  
 
Further Studies 
Extensions to the hierarchical model proposed in this study to identify AEU can be considered. 
First, the model can incorporate information of the mapping of the exons to the gene. In addition, 
the distance between the exons can be accommodated on the variance-covariance matrix. This 
would allow modeling of potentially higher dependencies between proximal exons relative to 
distant exons. Second, the model can incorporate information on different splicing scenarios [3].  
In this study, the vast majority of the exons within a gene mapped to one strand and few exons 
mapped to the other strand. Thus, AEU was studied among the exons that mapped to the most 
frequent strand. When sufficient information on both strands within a gene is available, our 
model allows the consideration of information across strands.  This model would allow the study 
of sense-antisense gene overlap and its impact on AS and regulation of gene expression 
following the work of Sorana Morrissy et al. Their work suggested an antisense transcription-
mediated mechanism of splicing regulation in human cells [69]. 
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Conclusions  
In conclusion, AEU is a complex process and thus the detection and characterization of AEU 
associated with survival is challenging. The hierarchical model developed in this study allowed 
simultaneously, the detection of differential expression of exons within a gene and differentially 
expressed genes associated with survival. From a total of 25,403 genes investigated, 2477 multi-
exon and 13 single exon genes were associated with GBM. Most of the significant genes 
detected by the model have been previously associated to GBM (27.78%) or other type of cancer 
(36.11%). The AEU events detected for several genes (Egf, Herc2, Gpr98, Anapc1) were 
consistent with AS models in AceView. The hierarchical model can be applied to other cancer 
types and to indicators other than survival. 
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